MIME-Version: 1.0 Content-Type: multipart/related; boundary="----=_NextPart_01D7B08D.18DB6DF0" Este documento é uma Página da Web de Arquivo Único, também conhecido como Arquivo Web. Se você estiver lendo essa mensagem, o seu navegador ou editor não oferece suporte ao Arquivo Web. Baixe um navegador que ofereça suporte ao Arquivo Web. ------=_NextPart_01D7B08D.18DB6DF0 Content-Location: file:///C:/ACF69CEE/1112HTMLEN.htm Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="windows-1252"

<= span class=3DForte1>RELATIONSHIP BETWEEN THROMBOTIC EVENTS AND SARS-COV-2 INFECTION: A LITERATURE REVIEW

<= span class=3DStrong>RELAÇÃO ENTRE EVENTOS TROMBÓTICOS E INFECÇÃO PELA SARS-COV-2: UMA REVISÃO DE LITERATURA

Tahissa Frota Cavalcante[1] * Cris= tefânia Meirú de Lima[2] * José Erivelton de Souza Maciel Ferreira[3] * Osmar Rodrigues Paixão Ne= to[4] * Rafaella Pessoa Moreira[5] * Viviane Nóbrega * Goularte Azevedo[6]

 

ABSTRACT

Objective: to present the knowledge produced about thrombotic events and their relationship with SARS-CoV-2 infection. Method:= an integrative literature review study, carried out in May and June 2020, in f= our databases/virtual libraries/portals and academic search engines, with the following keywords: coronavirus, SARS and thrombus (Pubmed, Cochrane and Science Direct) and SARS Virus and Blood Coagulation Disorders (Virtual Hea= lth Library). After the search, 263 studies were found and with the use of inclusion and exclusion criteria, 59 works remained. Results: the studies showed that the chances of occurrence of thrombotic events increase in older people with comorbidities. In addition, the most prevalent thrombotic event= s in patients affected by the disease were microvascular pulmonary thrombosis, l= ower limb venous thromboembolism, acute coronary syndrome and stroke. The assess= ment and follow-up of patients, especially those hospitalized in the Intensive C= are Unit, regarding their inflammatory state and their hypercoagulability marke= rs are important for early detection and decision-making for the administratio= n of anticoagulant therapies. Nursing is essential for the follow-up and monitor= ing of these patients. Final considerations: although the incidence of thrombot= ic events in people with COVID-19 worldwide is already better described in the literature, it is still necessary to produce more clinical and epidemiologi= cal studies to better explain this relationship; it is also important to determ= ine whether this disease can actually be classified as belonging to the group of vascular diseases.

Keywords: SARS-CoV-2; Coronavirus Infections; Thrombosis; Nursing; Critical Care Nursing= .

=  

RESUMO
Objetivo: apresentar o conhecimento produzido sobre eventos trombóticos e sua relação= com a infecção pela SARS-CoV-2. Método: estudo do tipo revisão integrativa da literatura, realizado nos meses de maio e junho de 2020, em quatro bases de dados/bibliotecas virtuais/portais e buscadores acadêmicos, com as seguintes palavras-chave: coronavírus, SARS and throm= bus (Pubmed, Cochrane and Science Direct) e Vírus da SARS and Transtornos da Coagulação Sanguínea (Biblioteca Virtual da Saúde). Após= a busca, foram encontrados 263 estudos e com o emprego dos critérios de inclu= são e exclusão restaram 59 trabalhos. Resultados: os trabalhos mostraram que= as chances de ocorrência de eventos trombóticos aumentam em pessoas mais idosa= s e com comorbidades. Além disso, os eventos trombóticos mais prevalentes nos pacientes acometidos pela doença foram trombose pulmonar microvascular, tromboembolismo venoso de membros inferiores, síndrome coronariana aguda e acidente vascular cerebral. A avaliação e acompanhamento de pacientes, principalmente os internados em Unidade de Terapia Intensiva, no tocante ao= seu estado inflamatório e os seus marcadores de hipercoagulabilidade são importantes para a detecção precoce e tomada de decisão para a administraçã= o de terapias anticoagulantes. A enfermagem é primordial para o acompanhamento e monitoramento desses pacientes. Considerações finais: embora a incidência d= os eventos trombóticos em pessoas com COVID-19 em âmbito mundial já esteja mel= hor descrita na literatura, ainda é necessário que se produzam mais estudos clínicos e epidemiológicos para melhor explicar essa relação; é importante ainda para que se possa determinar se de fato essa doença pode ser classifi= cada como pertencente ao grupo de doenças vasculares.

Palav= ras-chave: SARS-CoV-2; Infecções por Coronavirus; Trombo; Enfermagem; Enfermagem de Cuidados Críti= cos.

 


INTRODUCTION

Organizations and researchers around the world are concerned about the spread of this new coronavirus called SARS-CoV-2, the v= irus responsible for the outbreak of the new coronavirus 2019 disease (COVID-19), detected on December 31, 2019 in Wuhan, China(1).

Although the clinical manifestations caused by SARS-CoV-2 are similar to those caused by the common flu and a large percen= tage of people manifest mild symptoms, attention should be paid to the elderly a= nd people with comorbidities (such as cardiovascular diseases, diabetes mellit= us, asthma, and chronic obstructive pulmonary disease), pregnant women, and wom= en up to 45 days postpartum, because these conditions increase the chances for= the most serious forms of the disease. The main complications of SARS-CoV-2 infection are pneumonia, severe acute respiratory syndrome (SARS), renal failure, sepsis, cardiomyopathies, and increased clotting activity, which favors the occurrence of thrombotic events(2).=

Patients hospitalized in the intensive care unit (= ICU) are particularly in risk to develop pulmonary thromboembolism, so it is essential to take into account the associated fa= ctors, such as prolonged rest, the base illness, age, and comorbidities, in order = to perform anticoagulant prophylaxis(3). In addition, in February 2= 020, it was consistently demonstrated that SARS-CoV-2 causes a cytokines storm, which lead to the activation of the coagulation cascade that generate thrombotic complications(4-5).

Disseminated intravascular coagulation (DIC) is a secondary complication of serious infections, classically related to bacter= ial infections, malaria, hemorrhagic fevers associated with Dengue and Ebola viruses, and is now also related to SARS-CoV-2. One study detected ischemia (acro-ischemia) concomitant with the onset of dyspnea(6). This observation led researchers to consider the hypothesis of respiratory failu= re, due to the extensive pulmonary capillary obstruction by thrombi, and that t= he DIC may be playing an important role in hypoxemia, as well as in the morbid= ity and mortality results of ICU patients with COVID-19(6).

Because the disease is currently a pandemic, sever= al research questions are emerging as the disease progresses and manifests its= elf in different parts of the world. Research has been carried out and has alre= ady helped to clarify some themes such as the genome of the virus, the main for= ms of virus transmission and disease prevention, the search for effective and = safe drugs to treat the infection, and the formulation and testing of vaccines. However, much research is still needed to deepen the issues listed above.

In this context, the following questions arose: a) What is the incidence of thrombotic events in patients with SARS-CoV-2 worldwide? b) What are the most common thrombotic events in patients with SARS-CoV-2? c) Is there a difference in the incidence of these thrombotic events with respect to sex, age group and previous presence of comorbiditie= s? d) What are the most common clinical and laboratory manifestations of thrombotic events in patients with SARS-CoV-2? e) Is there a decrease in morbidity and mortality in patients with SARS-CoV-2 treated with anticoagul= ant and/or cardiovascular protector agents?

In view of the aforementioned facts, this study's = main objective is to present the current knowledge about thrombotic events relat= ed with SARS-CoV-2 infection. The relevance of this study lies in the fact that SARS-CoV-2 is a novel virus that can be easily spread and cause a significa= nt number of deaths in the world population, as well as important and serious complications such as thrombotic events. Thus, studies are needed to elucid= ate the issues related to thrombotic events in patients with COVID-19. Its relevance is also given because it presents a synthesis of many works that = have been published on the topic COVID-19, providing relevant information to professional nurses and others that make up the interdisciplinary health te= ams.

 

METHO= DS

=  

To accomplish this study, the literature review was chosen as the objective was to synthesize research results on a limited top= ic, in a systematic and organized manner, contributing to the deepening of knowledge(7). The steps of the literature review were: identification of the research questions, literature search, data evaluatio= n, data analysis, and presentation(8).

 

Identification of the research questions

 

The search was carried out on the topic of interes= t: coagulopathies and thrombotic events related to SARS-CoV-2 infection. To ga= ther knowledge about this theme, an integrative literature review was conducted = with the following purpose: To present the current knowledge about thrombotic ev= ents related with SARS-CoV-2 infection.

As already mentioned, the research questions were:= a) What is the incidence of thrombotic events in patients with SARS-CoV-2 worldwide? b) What are the most common thrombotic events in patients with SARS-CoV-2? c) Is there a difference in the incidence of these thrombotic events with respect to sex, age group and previous presence of comorbiditie= s? d) What are the most common clinical and laboratory manifestations of thrombotic events in patients with SARS-CoV-2? e) Is there a decrease in morbidity and mortality in patients with SARS-CoV-2 treated with anticoagul= ant and/or cardiovascular protector agents?

=  

Literature search

 

The following databases were searched: Virtual Hea= lth Library (which contains the LILACS, BDENF, WHO-IRIS, PAHO-IRIS, and SCIELO = databases), Pubmed (wich contains the Medical Literature An= alysis and Retrieval System Online database), Cochrane and Science Direct (one of = the largest sources of health research databases accessed through the Elsevier portal).

The decision to use these diverse databases, porta= ls, and libraries, was intended to expand the scope of the research and thus minimize possible bias. The search strategy employed a combination of speci= fic descriptors of each database.

The MeSH terms "coronavirus", "SARS", and "thrombus" were used in Pubmed, Science Dir= ect, and Cochrane databases. The DeCS structured and trilingual vocabulary descriptors in the health sciences "SARS Virus" and "Blood Coagulation Disorders" in Portuguese and their respective synonyms in English and Spanish were used in the Virtual Health Library.

We highlight that initially the search was perform= ed using controlled descriptors in each database. However, due to the small nu= mber of studies, the descriptors were used as keywords, expanding the scope of t= he research. The inclusion criteria established for the studies were: a) full-= text articles investigating the theme of coagulopathies and thrombotic events related to SARS-CoV-2 infection; and b) studies that answer at least one of= the research questions.

The literature search was conducted in May 2020 and updated in June 28, 2020. Each database was accessed in a single day, with a recording of the search pages. The selection of studies was carried out in = the following days, through reading of the titles and abstracts. When necessary, the full text was read to check whether it met the inclusion and exclusion criteria.

Figure 1 displays a flowchart describing the selection process of the evaluated stud= ies.


 

 

        Figure 1<= span lang=3DEN-US style=3D'font-size:12.0pt;font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-US;mso-farea= st-language: PT-BR'> - Flowchart of selection of works selected from the databases selec= ted for this integrative review.

 

 

 

 

 

 

 

 

 

 

 

 


       Source: The authors (2020).

 


Data evaluation - methodological quality

 

The methodological quality of the studies was evaluated in June 2020 based on their levels of evidence(9).

 

Data analysis – data reduction, display, comparison, and presentatio= n

 

The last steps of the <= span class=3DSpellE>literarure review are similar, they are presented in a single section. All selected studies were synthesized according to the following characteristics: identification, methodological description, resu= lts, and level of evidence. Data were presented in a qualitative way using major themes for categorization, as follows: relationship between thrombotic events and sociodemographic and clinical factors in patients with SARS-CoV-2; most common thrombotic events in patie= nts with SARS-CoV-2 with some clinical and laboratory findings; and results of treatments for this clinical situation.

 

Ethical aspects

 

Regarding ethical aspects, there was no need to send the project to = the Research Ethics Committee of the University of International Integration of= Lusofonia Afro-Brazilian, in accordance with Resoluti= on 466/2012(10), as it is an integrative review study.

RESUL= TS

 

The results fr= om the methodological quality assessment of the studies based on their levels = of evidence(9) is shown in Table 1.


 

Table 1 – Description of the methodological quality assessment of the articles incl= uded in this integrative review.

Levels of Evidence

Absolute frequency of studies

Relative frequency of= studies

1

1(41)<= /p>

2.0%

2

0

0.0%

3

0

0,0%

4

6(19,28,32,36,37,62)<= /p>

11.1%

5

20(11,13,22,23,25,27,29,30,33-35,43-46,49,52,55,= 68,70)

37.0%

6

17(15,20,21,24,26,40,42,47,48,53,54,56-58,61,63)=

31.4%

7

10(14,16,17,31,38,51,60,64,65,69)

18.5%

Source: The authors (2020).


Table 1 shows that most studies included in this review are literature reviews, descriptive studies, and case reports. However, it is opportune to consider that the COVID-19 pandemic is a major health emergency in global public hea= lth, therefore, health information is relevant even from studies with a low leve= l of evidence. The exchange of information between health workers and the consta= nt update of knowledge about the novel coronavirus raise research questions and stimulate the development of case reports, descriptive studies, and literat= ure reviews. Such studies can serve as a basis for the development of research = with more robust methods and can enhance the clinical practice through evidence-based decision making.

The results are presented according to the following thematic categories: relationship betw= een thrombotic events and sociodemographic and clinical factors in patients with SARS-CoV-2; most common thrombotic events in patients with SARS-CoV-2 with = some clinical and laboratory findings; and results of treatments for this clinic= al situation.

 

Relationship between thrombotic events and sociodemographic and clinical factors in pati= ents with SARS-CoV-2

 

Evidence of abnormal coagulation parameters associ= ated with COVID-19 appeared at the beginning of reports from China(= 11). A study developed with the first 99 hospitalized patients in Wuhan(= 12) found that in 36% of the patients had high D-dimer, increased inflammatory biomarkers such as inteleukin-6, high erythrocyte sedimentation volume, and high C-reactive protein. Thrombocytopenia was pre= sent in only 12% of patients and four died of septic shock(= 12).

A number of authors(13-17) referenced the study by Tang et al.(18) on coagulopathies and COVID-19. Such research= (18) evaluated 183 patients with SARS-CoV-2, among which 21 patients (11.5%) died. From the 21 patients who died 71% met the criteria of the International Society for Thrombosis and Homeostasis for disseminated intravascular coagulation compa= red with 0.6% of the surviving patients.

Worldwide, the= re are no population-based or multicenter studies on the prevalence of thrombo= tic events in people with SARS-CoV-2.

Several studie= s(13,19-35) point out that most of the thrombotic events related to SARS-CoV-2 occur in elderly people, male, and patients with pre-existing chronic diseases such as cardiovascular, cerebrovascular, lung, cancer, liv= er diseases, nephropathies, obesity, and diabetes mellitus.<= /p>

A st= udy(36) about venous thromboembolism in patients with COVID-19 based on autopsy findings found that the presence of neurodegenerative diseases is a risk fa= ctor for thrombotic complications in patients with SARS-CoV-2. An Italian cohort study(37) observed that fibrinogen values ​​appeared= to be higher in women affected by COVID-19 compared to the control group. A nonsignificant trend towards increased fibrinogen levels has been demonstrated in male patients. Patients with SARS and COVID-19 tend to have significant levels of fibrinogen compar= ed to those without SARS, and D-dimer levels showed an insignificant upward tr= end.

Guidelines on the prevention and treatment of thromboembolism(38) recommend the assessment of the risk for venous thromboembolism based =
on different clinical conditions, such as: age over 40, three days in bed, =
laboratory confirmation of COVID-19 combined with one of following risk fac=
tors: presence of sepsis, presence of severe acute respiratory disease, hea=
rt failure, obesity, history of venous thromboembolism, acute exacerbation =
of obstructive pulmonary disease, acute stroke, acute coronary syndrome, va=
ricose veins in the lower limbs, cancer, inflammatory bowel disease, and ch=
ronic kidney failure.

Researchers(13,38-39) claim that pregnant women and those in the postpartum period with COVID-19 = are more likely to develop venous thromboembolism. This risk is heightened by a= ge over 35 years, history of venous thromboembolism, preeclampsia, delayed intrauterine growth, genetic thrombophilia, blood transfusion, postpartum infections, systemic lupus, heart disease, obesity, multiple pregnancies, a= nd postpartum hemorrhages(38-39).

A point of interest in the COVID-19 pandemic has been differences in the pattern of mortality in young people. Some of these patients have a worse prognosis, b= ut without predisposing risk factors. In Italy, high mortality rates have been observed in young patients(40). One explanation for this finding= may be mutations in the coagulation cascade or complement inhibitory factors, s= uch as complement factor H, which appears to exist in 1% of the Italian populat= ion(40).

However, a systematic review study(41) with meta-analysis of the impact of cerebrovascular and cardiovascular diseases on the severity and mortality o= f COVID-19 found that such diseases were associated with increased mortality, but gend= er, age, arterial hypertension, diabetes mellitus, and respiratory conditions d= id not influenced this association.

&nbs= p;

Most common thrombotic events in patients with SARS-CoV-2 with some clinical and laboratory findings

 

Thromboembolism related to the SARS-CoV-2 virus can be seen in the pulmonary vessels in addition to cases of acute fibrinous and organizing pneumonia. Pulmonary le= sion of small blood vessels is a common manifestation in patients dying from COV= ID 19, with microvascular thrombosis in the lungs and thromboembolism with hemorrhagic infarction in larger vessels. In COVID-19, microvascular thromb= osis is largely observed(21,24,25,28,30-34,36,42-46).

Several researchers(11,12,17,25-28,33,34,37,45,47-53) described the occurrence of manifestations of thrombotic events in patients with SARS-CoV -2 in addition to pulmonary thromboembolism, stroke, venous thromboembolism, acute myocardial infarctio= n, cerebral venous sinus thrombosis, disseminated intravascular coagulation, a= nd sepsis-induced coagulopathies.

Other studies(19,28,54) reported that small vessel thrombosis led to intestinal ischemia, cholestasis and distention of the gallbladder and acute infarction of organs such as spleen, liver and kidneys in people with COVID-19. A research(36) also described, based on autopsy results, that pulmonary emboli are due to deep venous thrombosis of the lower limbs and t= hat complications such as thrombosis in the prostate venous plexus are also pre= sent in people with SARS-CoV-2 infection.

Rega= rding cardiovascular complications related to COVID-19, these involve heart failu= re, myocarditis, pericarditis, vasculitis, and cardiac arrhythmias. The presence of microangiop= athy and microthrombi can also predispose the patient to microinfarctions in multiple organs, such as liver, heart or kidney, further exacerbating the s= tate of injury and multiple organ failure(29,50-51,55)<= /span>.

Two s= tudies described thrombotic events in the skin capillaries, which generate the necrotizing capillary lesion, manifesting through slightly purplish reticul= ated eruptions on the chest, legs and arms, consistent with livedo reticularis(56-57). The explanation for this manifestation is that as endothelial cells also express the ACE2 gene, SARS-CoV-2 may cause direct endothelial dysfunction after binding to ACE2, leading to subsequent thrombosis(15).

 Other research(40) developed on the anal= ysis of the deposition of the SARS-CoV-2 virus in five placentas reported that t= here was thrombosis in larger vessels of the fetal circulation, frank thrombosis= in three cases, while in the other two cases, vascular thrombosis confined to = the villi of the trunk was confirmed, generating poor fetal perfusion due to thrombosis in placental vessels.

The clinical and laboratory manifestations of thrombotic events in people with SARS-CoV-2 are correlated with the specific signs and symptoms of central venous thrombosis(26,48), stroke(41,47,49,53), acute myocardial infarction(13,21,29,41), pulmonary thrombosis(28= ,31,33,45,58), deep peripheral venous thrombosis(20), disseminated intravascular coagulation(14,45,58), and acute renal failure(53,59-60).

Rese= arch on intestinal abnormalities(19) found abnormalities in the intestinal wall of ICU patien= ts affected by SARS-CoV-2 = using CT scans. The researche= rs found gastrointestinal symptoms such as nausea, vomiting, diarrhea, abdomin= al pain, and thickening of the intestinal wall, associated with pneumatosis and portal venous gas due to mesenteric ischemia.

Regar= ding laboratory tests, several studies(11,16,17,24,30,46,49,61) cited high D-dimer values ​​as a predisposing factor for the occurren= ce of thrombotic events in patients with COVID-19.

 

Results of treatments for this clinical situation

Current reports demonst= rate benefits of heparins in the prophylaxis of thrombotic events in patients wi= th COVID-19. Treatments with low molecular weight heparin (enoxaparin) or unfractionated heparin have been adopted and the success of the treatment depends on age and D-dimer values. When the value of this marker exceeds six times the normal upper limit, mortality becomes lower with the treatment(22,55).

ICU patients with COVID= -19 should use higher doses of low molecular weight heparin, as it has been sho= wn that they develop pulmonary thromboembolism even with prophylactic treatmen= t. Thus, both ICU and regular ward patients, even receiving low molecular weig= ht heparin, are developing deep venous thrombosis or pulmonary embolism, which reinforces that heparin doses must be doubled in this clinical context(11,16,18,20,22-23,25,27,30,33,38,43,45,62-63).

Another study on pulmon= ary embolism in patients with COVID-19 added that there was an improvement in t= he antithrombotic effect when there was a change from enoxaparin to rivaroxaba= n(24). Researchers(25) add that for patients = with stroke and COVID-19 it seems reasonable to treat with = tPA. In addition, AT1 receptor blockers, such as losartan, may have a protective effect in stroke patients.

Researchers= (16,18,34,64) report the results on the use of intravenous immunoglobulin (IVIG) and anticoagulant therapy with low molecular weight heparin as early as possibl= e, especially when the number of circulating T and B lymphocytes decreases and inflammatory cytokines and D-Dimer increases drastically. Although intraven= ous immunoglobulin has been shown to be effective in treating patients with influenza and SARS, more clinical data is needed to determine immunoglobulin efficacy in patients with COVID-19.

It should be noted that preclinical studies(6= 6-67) document the anti-thrombotic effects of vitamin D supplementation. Research= ers also point out that most intervention studies do not clearly show the protective effects of vitamin D supplementation in preventing cardiovascular events. However, most studies have not evaluated people with severe vitamin= D deficiency(67-68). Vitamin D deficiency is a prevalent problem worldwide – 7% of the world population has severe deficiency and about 40% = have borderline levels of vitamin D in the body(66).

Regar= ding cardiovascular protection, two studies(29,51) describe that pati= ents with COVID-19 and cardiac injury must be closely monitored for the increase= in cardiac enzymes – the markers of cardiac stress, and that the administratio= n of cardioprotective agents is necessary.

 

DISCU= SSION

Among the explanations about the formation of micr= othrombi with lesions in several target organs, we find that the SARS-CoV-2 virus ha= s an extensive tissue distribution causing the release of a high number of pro-inflammatory cytokines (cytokine storm), promoting a systemic inflammat= ory response syndrome with an important impact on the hematopoietic system and hemostasis, leading to infarction of organs such as lungs, heart, liver, and kidneys(14,50,68).

It is= worth mentioning that specific changes in hemostasis are already present in the initial stage of the SARS-CoV-2 infection(11,18,37). COVID-19-associated coagulopathy due to acute systemic inflammatory respons= e is characterized by an elevation of several coagulation markers, such as D-dim= er (a fibrin or fibrinogen degradation product), concomitant increase in inflammatory markers (including C-reactive protein), and mild thrombocytope= nia(49,61).

Some hypotheses that justify the increased incidence of thrombotic events in older people a= nd with pre-existing chronic diseases are: a) the tendency of these people to have a higher D-dimer value(16,18,34); b) the use of antihypertensive drugs, such as ACE inhibitors and angiotensi= n II receptor blockers, which increase the expression of the ECA2 gene, and favor the replication of the SARS-CoV-2 virus(30); and c) alteration of the renin-angiotensin-aldosterone system that is intrinsically linked to the coagulation cascade and can aggravate the immunothromb= osis process, further stimulating the formation of microthrombi in COVID-19= (69).

There is strong evidence that occlusion and format= ion of microthrombi in small pulmonary vessels exists in critically ill patients with COVID-19 and that, therefore, the early application of anticoagulant therapy in these patients is important to improve the prognosis(18). Every patient at risk of deep venous thrombosis admitted to the ICU should receive some preventive treatment (pharmacological, mechanical, or both), as prevention is essential, as long as it is safe and effective. The nursing t= eam is essential in this process, from the administration of prescribed drugs to the performance of non-pharmacological measures that contribute as part of = this preventive treatment described.

Nurses and other professionals should also be awar= e of the signs and symptoms of thrombotic events manifested by patients with COVID-19, because it is proven to be a disease that can generate such complications, which require timely effective clinical decision-making. Such complications affect the morbidity and mortality profile, as described. This responsibility applies even more to the nursing team, as they are the professionals who most provide direct care to clients.

The recommendation for nurses and other health professionals who provide nursing care to critical or semi-critical patients in referral hospitals for COVID-= 19 is to closely monitor sick patients. It is noteworthy to pay attention to t= he signs and symptoms of thrombotic events, the inflammatory markers and the hypercoagulable state they present. In addition, they can early recognize t= he high risk of thrombosis in these patients, especially in the elderly with comorbidities, especially cardiovascular, pulmonary, endocrine - diabetes mellitus - and metabolic - obesity, for the early and effective implementat= ion of anticoagulant therapy.

Some = research questions were not answered, such as the incidence of thrombotic events in people with SARS-CoV-2 worldwide and the effects of cardiovascular protecti= ve drugs on the reduction of morbidity and mortality. It is important that researchers from the most diverse areas of health can seek to answer them o= ver time so that their findings are promptly published.

This literature review has the following implications: a) it brings an in-depth = and updated synthesis of the knowledge produced by researchers from different countries about serious complications arising from the SARS-CoV-2 virus, su= ch as thrombotic events; b) it can assist decision-making by doctors and nurse= s to monitor and treat COVID-19 patients; c) it describes knowledge gaps and research questions that need to be investigated further to contribute to the advancement of knowledge in the field; and d) in the context of this pandem= ic, studies involving the topic of infection by SARS-CoV-2 and COVID 19 are very important, regardless of the approaches, as this is a new disease and the knowledge that has been produced and disseminated has contributed to reduci= ng the severe impacts caused by the SARS-CoV-2 virus.

Many = issues highlighted in this integrative review need to be further investigated for further clarification, such as problems of thrombotic events related to SARS-CoV-2 virus infection in different continents; and whether there are proven effective protective factors (clinical, laboratory, pharmacological) that would decrease the chances of developing thrombotic events in people infected with SARS-CoV-2; and what are the effective tools used by the nurs= ing team to reduce the incidence of this problem in this population.

Other issues also raised, which also need to be investigated, were whether vitami= n D supplementation is effective in preventing thrombotic events in people with COVID-19; the comparison between non-pharmacological and pharmacological methods of preventing venous thrombosis in people with COVID 19; and follow= -up studies of people who have had COVID-19 to determine the incidence of thrombotic events at a later stage or to investigate the recurrence of new events among those who manifested some thrombotic disease at an early stage= of SARS infection. CoV-2.

 

FINAL CONSIDERATIONS

The s= tudies included in this review indicate that there is a relationship between the pathophysiology of SARS-CoV-2 infection and thrombotic events, through cyto= kine storm and disseminated intravascular coagulation. The literature also showed that the chances of occurrence of thrombotic events in COVID-19 increase in= the elderly and associated comorbidities. It also suggested that the most appropriate thrombotic events in this clinical setting were microvascular pulmonary thrombosis, lower limb venous thromboembolism, acute coronary syndrome, and stroke.

The assessment and follow-up of patients, especially those admitted to the ICU, regarding their inflammatory status and their hypercoagulability markers, s= uch as D-dimer, were considered important for early detection and decision-maki= ng regarding the administration of anticoagulants. Nursing is essential for the follow-up and monitoring of these patients, as well as for quick and effect= ive decision-making for the stability of the clinical picture of patients in cr= itical care until the arrival of other professionals who make up the intensive care team.

Discr= imination of thrombotic events in people with COVID-19 worldwide is already available= in the literature, but further clinical and epidemiological studies are still = needed to better explain this relationship. It is also important to determine whet= her this disease can really be classified as belonging to the group of vascular diseases. The results of this study can support research in this thematic l= ine.

 

REFERENCES

1. World Health Organization.  Coronavírus (COVID-19) Dashboard. Disponível em: = https://covid19.who.int/ Acessed= : 05 de maio de 2020.

2. Strabelli TMV, Uip DE. COVID-19 e o Coração. Arq Bras= Cardiol 2020 Mar; 114(4). DOI: https://doi.org/10.36660/abc.2020= 0209 

3. Mascarello MG, Vanonni G, Indavere A, Waistein KM, Estrella ML, Rodrig= uez SG et al. Tromboembolismo de pulmón - sospecha clínica y correlación anatomopatológica. Medicina (B Aires) 2020; 80(2): 97-102.

4. Han H, Yang L, Liu R, Liu F, Wu KL, Li J et = al. Prominent changes in blood coagulation of patients with SARSCoV- 2 infection. Clin Chem Lab Med 2020; 58(7):1116-1120. DOI: 10.1515 / cclm-2020-0188

5. Wu C, Chen X, Cai Y, Xia JA, Zhou X, Xu, S et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients W= ith Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2= 020; e200994. DOI:   10.1001 / jamainternmed.2020.0994

= 6. Negri EM, Piloto BM, Morinaga LK, Jardim CVP, L= amy SAE, Ferreira MA et al. He= parin Therapy improving hipóxia in COVID-19 patients = – a case series. MedRxiv= 2020. DOI: https://doi.org/10.1101/2020.04.1= 5.20067017

7. Mendes KDS, Silveira RCCP, Galvão CM. Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto contexto – enferm 2008; 17(4):758-= 764. DOI: https://doi.org/10.1590/S0104-07072008000400018=

8. Whittemore R, Knafl K. The integrative revie= w: updated methodology. J Adv Nurs 2005; 52(5):546-553. DOI:  https://doi.org/10.1111/j.1365-26= 48.2005.03621.x

9. Melnyk BM, Fineout-Overholt E. Making the ca= se for evidence-based practice. In: Melnyk BM, Fineout-Overholt E. Evidence-ba= sed practice in nursing & healthcare - a guide to best practice. Philadelphia: = Lippincot Williams& Wilkins; 2005.

= 10. Brasil Resolução No 466/12. Diretrizes e Normas regulamentadoras= das pesquisas que envolvem seres humanos. Brasília: Conselho Nacional de Saúde; 2012.

11. Connors JM, Levy JH. COVID-19 and = Its Implications for Thrombosis and Anticoagulation. Blood 2020 Apr 27; 135(23): 2033-2040. DOI: <= span style=3D'color:black;text-decoration:none;text-underline:none'>https://doi.= org/10.1182/blood.2020006000

12. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et= al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395:507-13. DOI: https://doi.org/10.1016/S0140-673= 6(20)30211-7

13.Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. Journal of the American College of Cardiology 2020. DOI: https://doi.org/10.1016/j.jacc.20= 20.04.031

14. Song JC, Wang G, Zhang W, Zhang Y,= Li WQ, Zhou Z. Chinese expert consensus on diagnosis and treatment of coagulat= ion dysfunction in COVID-19. Military Medical Research 2020;7(1). DOI: https://doi.org/10.1186/s40779-02= 0-00247-7

15. Thomas C. Reply to: “A Dermatologic Manifestation of COVID-19: Transient Livedo Reticularis.” Journal of the American Academy of Dermatology 2020. DOI: https://doi.org/10.1016/j.jaad.20= 20.04.164

= 16. Thachil J, Tang N, Gando = S, Falanga A, Cattaneo M, Le= vi M, et al. ISTH interim guidance on recognition a= nd management of coagulopathy in COVID-19. J Thromb Haemost 2020. DOI: https://doi.org/10.1111/jth.14810=

17. Vivas = D, Roldán V, Esteve-Pastor M= A, Roldán I, Tello-Montoliu = A, Ruiz-Nodar J M, et all. DOI: https://doi.org/doi:10.1016/j.recesp.2020.04.006

18. Tang N, Li D, Wang = X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020. DOI:  https://doi.org/10.1111/jth.14768= =

19. Bhayana R, Som A, Li MD, Carey DE, Anderson MA, Blake MA, et al.= Abdominal Imaging Findings in COVID-19: Preliminary Observations. Radiology 2020 May = 11; 201908. DOI: https://doi.= org/10.1148/radiol.2020201908

20. Bozzani A, Arici V, Franciscone MM, = Danesino V, Cascina A, Ticozzelli G, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Infection and the Upper Limb Deep Vein Thrombosis Risk. Ann Vasc Surg 2020 = Apr 23; S0890-5096(20)30356-3. DOI: https://doi.org/10.1016/j.avsg.20= 20.04.037

21. Buja L= M, Wolf D, Zhao B, Akkant B, McDonald M, Lelenwa L, et al. Emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): report of three autop= sies from houston, texas= and review of autopsy findings from other united states cities. J Card Fail 2020 Apr; PII: S1054-8807(20)30037-5. DOI: https://doi.org/10.1016/j.carpath= .2020.107233

22. Harenberg J, Favaloro E. COVID-19: Progression of Disease and Intravascular Coagulation - Present Status and Future Perspectives. Clin Ch= em Lab Med 2020 May 14; 58(7): 1029-1036. DOI: https://doi.org/10.1515/cclm-2020= -0502

23. Giannis D, Zi= ogas IA, Gianni P. Coagulation Disorders in Coronavirus Infected Patients: COVID= -19, SARS-CoV-1, MERS-CoV and Lessons From the Past. J Clin Virol 2020 Apr 9; 12= 7: 104362. DOI: 10.1016/j.jcv.2020.104362.

24. Griffin DO, Jensen A, Khan M, Chin= J, Chin K, Saad J, et al. Pulmonary Embolism and Increased Levels of d-Dimer in Patients with Coronavirus Disease. Emerg Infect= Dis 2020 Apr 29; 26(8). DOI: 10.3201/eid2608.201477.

25. Hess DC, Elda= hshan W, Rutkowski E. COVID-19-Related Stroke. Transl Stroke Res 2020 May 7; 11(3): 322-325. DOI: 10.1007/s12975-020-00818-9.

26. Hughes C, Nichols T, Pike M, Subbe C, Elghenzai S. Cer= ebral Venous Sinus Thrombosis as a Presentation of COVID-19. Eur J Case Rep Intern Med 2020 Apr 29; 7(5): 001691. DOI: 10.12890/2020_001691.=

27. Kollias A, Kyriakoulis KG, Dimakakos E, Pou= lakou G, Stergiou GS, Syrigos K. Thromboembolic Risk = and Anticoagulant Therapy in COVID-19 Patients: Emerging Evidence and Call for Action. Br J Haematol 2020 May 4; 189(5): 846-8= 47. DOI: 10.1111/bjh.16727.

28. Lax SF, Skok<= /span> K, Zechner P, Kessler HH, Kaufmann N, Koelblinger C, et al. Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center, Clinicopathologic Case Series. Ann Intern Med 2020 May 14; M20-2566. DOI: 10.7326/M20-2566.

29. Liu PP, Blet<= /span> A, Smyth D, Li H. The Science Underlying COVID-19: Implications for the Cardiovascular System. Circulation<= span style=3D'font-size:12.0pt;font-family:"Times New Roman",serif;color:black'>= 2020 Apr 15. DOI: 10.1161/CIRCULATIONAHA.120.047549.<= /o:p>

= 30. Alijotas-Reig J, Esteve-Valverde E, Belizna C, Selva-O'Callaghan A, Pardos-Gea J, Quintana A, et al. Im= munomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therap= y: A comprehensive review. Autoimmun Rev 2020 Apr; P= II: S1568-9972(20)30131-2. DOI: https://doi.org/10.1016/j.autrev.= 2020.102569

31. Saba L, Sverz= ellati N. Is COVID Evolution Due to Occurrence of Pulmonary Vascular Thrombosis? <= /span>= J Thorac Imaging 2020 Apr 28; 10.1097/RTI.0000000000000530. DOI: 10.1097/RTI.0000000000000530.

= 32 Spiezia L, Boscolo A, Poletto F, Cerruti L, Tiberio I, Campello E, et al. COVID-19-Related Severe Hypercoagulability in Pati= ents Admitted to Intensive Care Unit for Acute Respiratory Failure. Thromb Haemost 2020 Apr 2= 1; 120(6): 998-1000. DOI: 10.1055/s-0040-1710018.

33. Tal S, Spectr= e G, Kornowski R, Perl L. Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far? Acta Haematol 2020 May 12; 1-8. DOI: 10.1159/000508233.

34. Thachil J, Srivastava A. SARS-2 Coronavirus-Associated Hemostatic Lung Abnormality in COVID-19: Is It Pulmonary Thrombosis or Pulmonary Embolism?  Semin Thromb Hemost 2020 May 12= . DOI: 10.1055/s-0040-1712155.

35. Verdecchia P, Cavallini C, Spanevello= A, Angeli F. The Pivotal Link Between ACE2 Defi= ciency and SARS-CoV-2 Infection. Eur J Intern Med 2020 Apr 20; 76: 14-20. DOI: 10.1016/j.ejim.2020.04.037.

36. Wichmann D, S= perhake JP, Lütgehetmann M, Steure= r S, Edler C, Heinemann A, et al. Autopsy Finding= s and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Stud= y. Ann Intern Med 2020 May 6; M20-2003. DOI: 10.7326/M20-2003.

37. Di Micco P, Russo V, Carannante N, Imp= arato M, Rodolfi S, Cardillo G, et al. Clotting Facto= rs in COVID-19: Epidemiological Association and Prognostic Values in Different Clinical Presentations in an Italian Cohort. J Clin Med 2020 May 7; 9(5):13= 71. DOI: 10.3390/jcm9051371.

38 <= span lang=3DEN-US style=3D'font-size:12.0pt;font-family:"Times New Roman",serif; color:black;mso-ansi-language:EN-US'>Zhai Z, Li C, Chen Y, Gerotziafas G, Zhang Z, Wan J, et al. Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines. Thromb = Haemost. 2020;120(6):937-948. doi:10.1055/s-0040-1710019

39. Leffert L, Butwick A, Carvalho B, et al; members of the= SOAP VTE Taskforce. The Society for Obstetric Anesthesia and Perinatology Consen= sus Statement on the anesthetic management of pregnant and postpartum women receiving thromboprophylaxis or higher dose anticoagulants. Anesth Analg 2018;126(03):928–

944.=

40. Mulveya JJ, Magrob CM, Mab LX, Nuovoc= GJ, Baergenb RN. Analysis of complement deposition and vi= ral RNA in placentas of COVID-19 patients. Ann Diagn Patho= l 2020; 46:151529. DOI: https://doi.= org/10.1016/j.anndiagpath.2020.151529

41. Pranata R, Huang I, Lim MA, Wahjoepramono PEJ, July J. Impact of Cerebrovascular = and Cardiovascular Diseases on Mortality and Severity of COVID-19 – Systematic Review, Meta-analysis, and Meta-regression. Journal of Stroke and Cerebrovascular Diseases 2020. https://doi.= org/10.1016/j.jstrokecerebrovasdis.2020.104949

= 42. Audo A, Bonato V, Cavozza C, Maj G, Pistis G, Secco GG. Acute Pulmonary Embolism in SARS-CoV-2 Infection Treated with Surgical Embolectomy. Ann Thorac S= urg 2020 Apr; PII: S0003-4975(20)30616-0. DOI: https://doi.org/10.1016/j.a= thoracsur.2020.04.013

43. Tersalvi G, Vicenzi M, Calabretta D, = Biasco L, Pedrazzini G, W= interton D. Elevated troponin in patients with Coronavirus Disease 2019 (COVID-19): possible mechanisms. J Card Fail 2020 Apr; PII: S1071-9164(20)30357-2 DOI: = https://doi.org/10.1016/j.cardfai= l.2020.04.009

44. Zhang J, Xie B, Hashimoto K. Curre= nt status of potential therapeutic candidates for the COVID-19 crisis. Brain <= span class=3DSpellE>Behav Immun 2020 Apr; PII: S0889-1591(20)30589-4. DOI: https://doi.= org/10.1016/j.bbi.2020.04.046

45. Whyte CS, Morrow GB, Mitchell JL, Chowdary P, Mutch NJ. Fibrinolytic Abnormalitie= s in Acute Respiratory Distress Syndrome (ARDS) and Versatility of Thrombolytic Drugs to Treat COVID-19. J Thromb Haemost 2020 Apr 23. DOI: 10.1111/jth.14872.

46. Xie M, Chen Q. Insight into 2019 n= ovel coronavirus - An updated interim review and lessons from SARS-CoV and MERS-= CoV. Int J Infect Dis 2020 Mar; 94(2020): 119-24. DOI: https://doi.org/10.1016/j.ijid.20= 20.03.071

47. Avula = A, Nalleballe K, Narula N, Sapozhni= kov S, Dandu V, Toom S, et al. COVID-19 presenting as stroke. Brain Behav Immun 2020 Apr; PII: S0889-1591(20)30685-1. DOI: https://doi.= org/10.1016/j.bbi.2020.04.077

48. Dahl-Cruz F, Guevara-Dalrymple N, López-Hernández N. Cerebral Venous Thrombosis and SARS-CoV-2 Infection. Rev Neurol 2020 May 16; 70(10): 391-392. DOI: 10.33588/rn.7010.2020204.

49. Divani= AA, Andalib S, Napoli SD, Lattanzi S, Hussain S, Biller J, et al. Coronavirus disease 2019 and stroke: clinical manifestations and pathophysiological insights. J Stroke Cerebrovasc Dis 2020 May; PII: S1052-3057(20)30347-5. DOI: https://doi.= org/10.1016/j.jstrokecerebrovasdis.2020.104941

50. Katal = S, Balakrishnan S, Gholamrezanezhad A. Neuroimaging findings in COVID-19 and other coronavirus infections: a systematic review = in 116 patients. AJNR Am. J. Neuroradiol 2020; PII: S0150-9861(20)30204-2. Doi: https://doi.org/10.1016/j.neurad.= 2020.06.007

51. Mahajan K, Chandra KS. Cardiovascu= lar comorbidities and complications associated with coronavirus disease 2019. M= ed J. Armed Forces India 2020 May; Doi: https://doi.org/10.1016/j.mjafi.2= 020.05.004

52. Pedicelli A, = Valente I, Pilato F, Distefano M, Colosi= mo C. St= roke priorities during COVID-19 outbreak: acting both fast and safe. J Stroke Cerebrovasc Dis 2020 May; 104922. DOI: https://doi.= org/10.1016/j.jstrokecerebrovasdis.2020.104922.

53. Wright FL, Vogler TO, Moore EE, Mo= ore HB, Wohlauer MV, Urban S, et all. Fibrinolysis Shutdown Correlates to Thromboembolic Events in Severe COVID-19 Infection. Journal of the American College of Surgeons. 2020. https://doi.= org/10.1016/j.jamcollsurg.2020.05.007

54. Barry O, Mekk= i A, Diffre C, Seror = M, Hajjam MEL, Carlier RY. Arterial and venous abd= ominal thrombosis in a 79-year-old woman with COVID-19 pneumonia. Radiol Case Rep 2020 Apr; PII: S1930-0433(20)30158-8. DOI: https://doi.org/10.1016/j.radcr.2= 020.04.055

55. Ganatra S, Dani SS, Shah S, Asnani S, Neilan TG, Lenihan D, et al. Management of Cardiovascular Disease During Coronavirus Disease (COVID-19) Pandemic. Trends Cardiovas Med 2020 June 5; 21:14. Doi: https://doi.= org/10.1016/j.tcm.2020.05.004

56. Magro = C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associ= ated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. = Transl= Res 2020. PII: S1931-5244(20)30070-0. DOI: https://doi.org/10.1016/j.trsl.20= 20.04.007

57. Rebollar JCO. Manifestaciones cutaneas de la infeccion por covid<= /span> 19. a proposito de un caso. Medicina Clínica. 2020. https://doi.org/10.1016/j.medcli.2020.04.002

58. Xing C, Li Q, Du H, Kang W, Lian J, Yuan L. Lung Ultrasound Findings in Patients With COVID-19 Pneumonia. Crit Care 2020 Apr 28; 24(1): 174. DOI: 10.1186/s13054-020-02876-9.

59. Post A, Deurw= aarder ESG, Bakker SJL, Haas RJ, Meurs M, Gansevoort R= T, et al. Kidney Infarction in Patients With COVID-19. Am J Kidney Dis. 2020; XX(XX):1- 5. Doi: https://doi.= org/10.1053/j.ajkd.2020.05.004

60. Selby NM, For= ni LG, Laing CM, Horne KL , Evans RDr , Lucas BJ, = et al. Covid-19 and acute kidney injury in hospital: summary of NICE guidelines. B= MJ. 2020; 369: m1963. Published 2020 May 26. doi:10.1136/bmj.m1963

61. Kaur P, Qaqa<= /span> F, Ramahi A, Shamoon Y, Singhal M, Shamoon F, Maro= ules M, Singh B. Acute upper limb ischemia in a patient with COVID-19. Hematol Oncol Stem Cell Ther 2020 May; PII: S1658-3876(20)30096-0. DOI: https://doi.org/10.1016/j.hemonc.= 2020.05.001

62. Helms J, Tacq= uard C, Severac F, Leonard-Lora= nt I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection= : a multicenter prospective cohort study. Intensive Care Med 2020 Jun; 46(6): 1089-1098. DOI: 10.1007/s00134-020-06062-x.

63. Hirshberg A, Kern-Goldberger AR, D. Levine L, Pierce-Williams R, Short WR, Parry S, et al. Care of critically i= ll pregnant patients with COVID-19: a case series. Am J Obstet Gynecol 2020 Ap= r; PII: S0002-9378(20)30515-9. DOI: https://doi.org/10.1016/j.ajog.20= 20.04.029

64 Raucci = F, Mansour AA, Casillo GM, Saviano A, Caso F, Scar= pa R, et all. Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms. Autoimmunity Reviews. 2020. https://doi.org/10.1016/j.autrev.= 2020.102572

65. Gomez JMQ, Castillo ME, Bouillon R. Vitamin D Receptor stimulation to reduce Acute Respiratory DistressSyndrome (ARDS) in patients with Coronavirus SARS-CoV-2 infections. J Steroid Biochem 2020 May 4; PII: S0960-0760(20)30244-2. DOI: = https://doi.org/10.1016/j.jsbmb.2= 020.105719

66. Bouillon R. Vitamin D status in Africa is w= orse than in other continents. Lancet Glob. Heal 2020; 8:e20-e21. DOI: 10.1016 / S2214-109X (19) 30492-9=

67. Bouillon R, M= arcocci C, Carmeliet D, Bikle JH, White B, Dawson, P et al. Skeletal and extraskeletal actions of vitamin D: current evidence and outstanding questions. Endocr. Rev 2019; 40:1109-1151. DOI: 10.1210/er.2018-00126=

68. Weir EK, Then= appan T, Bhargava M, Chen Y. Does vitamin D deficiency increase the severity of COVID-19? Clin Med 2020 Jun 5. DOI: 10.7861/clinmed.2020-0301.=

69. Debuc = B, Smadja DM. Is COVID-19 a New Hematologic Disease? Ste= m Cell Rev and Rep. 2020. <= span style=3D'color:black;text-decoration:none;text-underline:none'>https://doi.= org/10.1007/s12015-020-09987-4.

70. Henry MB, Vik= se J, Benoit S, Favaloro EJ, Lippi G. Hyperinflamm= ation and Derangement of Renin-Angiotensin-Aldosterone System in COVID-19: a novel hypothesis for clinically suspected hypercoagulopathy<= /span> and microvascular immunothrombosis. = Clin Chim Acta 2020 Apr; PII: S0009-8981(20)30183-2. DOI: https://doi.= org/10.1016/j.cca.2020.04.027.

 

Autor correspondente

José Erivelton de S= ouza Maciel Ferreira. Rua Antônia Vicente, Baturité-CE 62.760-000, +558599811657= 8, eriveltonsmf@gmail.com.

=  

Submission= : 2021-05-14

Approval= : 2021-06-12

 

 



[1] Enfermeira. D= outora em Enfermagem. Professora do curso de Enfermagem e do Programa de Pós-Gradu= ação em Enfermagem da Universidade da Integração Internacional da Lusofonia Afro-Brasileira (UNILAB), Redenção-Ceará, Brasil. Orci= d: https://orcid.org/0000-0002-= 7758-4273

[2] Acadêmica do curso de graduação em Enfermagem da Universida= de da Integração Internacional da Lusofonia Afro-Brasileira (UNILAB), Redenção-CE, Brasil. Orcid: https://orcid.org/0000-0001-= 8919-4988

[3] Enfermeiro. Especialista em Enfermagem Cirúrgica. Pós-graduando lato sensu em Enfermagem do Trabalho. Mestrando em Enfermagem= da Universidad= e da Integração Internacional da Lusofonia Afro-Brasileira (UNILAB), Redenção-Ce= ará, Brasil. Orcid: https://orcid.org/0000-0003-= 2668-7587

[4] Acadêmico do curso de graduação em Enfermagem da Universida= de da Integração Internacional da Lusofonia Afro-Brasileira (UNILAB), Redenção-Ce= ará, Brasil. Orcid: https://orcid.org/0000-0003-4183-6018

[5] Enfermeira. D= outora em Enfermagem. Professora do curso de Enfermagem e do Programa de Pós-Gradu= ação em Enfermagem da Universidade da Integração Internacional da Lusofonia Afro-Brasileira (UNILAB), Redenção-Ceará, Brasil. Orci= d: https://orcid.org/0000-0003-= 2341-7936

[6] Enfermeira. Especialista em Enfermagem em Nefrol= ogia. Mestranda em Enfermagem da Universidade da Integração Internacional da Lusofonia Afro-Brasileira (UNILAB), Redenção-Ceará, Brasil. Orci= d: https://orcid.org/0000-0002-0134-0694<= o:p>

 

 

------=_NextPart_01D7B08D.18DB6DF0 Content-Location: file:///C:/ACF69CEE/1112HTMLEN_arquivos/themedata.thmx Content-Transfer-Encoding: base64 Content-Type: application/vnd.ms-officetheme UEsDBBQABgAIAAAAIQDp3g+//wAAABwCAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKyRy07DMBBF 90j8g+UtSpyyQAgl6YLHjseifMDImSQWydiyp1X790zSVEKoIBZsLNkz954743K9Hwe1w5icp0qv 8kIrJOsbR12l3zdP2a1WiYEaGDxhpQ+Y9Lq+vCg3h4BJiZpSpXvmcGdMsj2OkHIfkKTS+jgCyzV2 JoD9gA7NdVHcGOuJkTjjyUPX5QO2sB1YPe7l+Zgk4pC0uj82TqxKQwiDs8CS1Oyo+UbJFkIuyrkn 9S6kK4mhzVnCVPkZsOheZTXRNajeIPILjBLDsAyJX89nIBkt5r87nons29ZZbLzdjrKOfDZezE7B /xRg9T/oE9PMf1t/AgAA//8DAFBLAwQUAAYACAAAACEApdan58AAAAA2AQAACwAAAF9yZWxzLy5y ZWxzhI/PasMwDIfvhb2D0X1R0sMYJXYvpZBDL6N9AOEof2giG9sb69tPxwYKuwiEpO/3qT3+rov5 4ZTnIBaaqgbD4kM/y2jhdj2/f4LJhaSnJQhbeHCGo3vbtV+8UNGjPM0xG6VItjCVEg+I2U+8Uq5C ZNHJENJKRds0YiR/p5FxX9cfmJ4Z4DZM0/UWUtc3YK6PqMn/s8MwzJ5PwX+vLOVFBG43lExp5GKh qC/jU72QqGWq1B7Qtbj51v0BAAD//wMAUEsDBBQABgAIAAAAIQBreZYWgwAAAIoAAAAcAAAAdGhl bWUvdGhlbWUvdGhlbWVNYW5hZ2VyLnhtbAzMTQrDIBBA4X2hd5DZN2O7KEVissuuu/YAQ5waQceg 0p/b1+XjgzfO3xTVm0sNWSycBw2KZc0uiLfwfCynG6jaSBzFLGzhxxXm6XgYybSNE99JyHNRfSPV kIWttd0g1rUr1SHvLN1euSRqPYtHV+jT9yniResrJgoCOP0BAAD//wMAUEsDBBQABgAIAAAAIQAt LgC8nAcAAMsgAAAWAAAAdGhlbWUvdGhlbWUvdGhlbWUxLnhtbOxZzYsbyRW/B/I/NH2X9dWtj8Hy ok/P2jO2sWSHPdZIpe7yVHeJqtKMxWII3lMugcAm5JCFve0hhCzswi655I8x2CSbPyKvqlvdVVLJ nhkcMGFGMHSXfu/Vr9579d5T1d3PXibUu8BcEJb2/Pqdmu/hdM4WJI16/rPZpNLxPSFRukCUpbjn b7DwP7v361/dRUcyxgn2QD4VR6jnx1KujqpVMYdhJO6wFU7huyXjCZLwyqPqgqNL0JvQaqNWa1UT RFLfS1ECamcg4y2Y93i5JHPs39uqH1OYI5VCDcwpnyrlOJcxsIvzukKIjRhS7l0g2vNhpgW7nOGX 0vcoEhK+6Pk1/edX792toqNciMoDsobcRP/lcrnA4ryh5+TRWTFpEIRBq1/o1wAq93Hj9rg1bhX6 NADN57DSjIuts90YBjnWAGWPDt2j9qhZt/CG/uYe536oPhZegzL9wR5+MhmCFS28BmX4cA8fDrqD ka1fgzJ8aw/frvVHQdvSr0ExJen5HroWtprD7WoLyJLRYye8GwaTdiNXXqIgGoroUlMsWSoPxVqC XjA+AYACUiRJ6snNCi/RHOJ4iCg548Q7IVEMgbdCKRMwXGvUJrUm/FefQD9pj6IjjAxpxQuYiL0h xccTc05Wsuc/AK2+AXn7889vXv/45vVPb7766s3rv+dza1WW3DFKI1Pul+/+8J9vfuv9+4dvf/n6 j9nUu3hh4t/97Xfv/vHP96mHFZemePun79/9+P3bP//+X3/92qG9z9GZCZ+RBAvvEb70nrIEFujg j8/49SRmMSKmRD+NBEqRmsWhfyxjC/1ogyhy4AbYtuNzDqnGBby/fmERnsZ8LYlD48M4sYCnjNEB 404rPFRzGWaerdPIPTlfm7inCF245h6i1PLyeL2CHEtcKocxtmg+oSiVKMIplp76jp1j7FjdF4RY dj0lc84EW0rvC+INEHGaZEbOrGgqhY5JAn7ZuAiCvy3bnD73Boy6Vj3CFzYS9gaiDvIzTC0z3kdr iRKXyhlKqGnwEyRjF8nphs9N3FhI8HSEKfPGCyyES+Yxh/UaTn8Iacbt9lO6SWwkl+TcpfMEMWYi R+x8GKNk5cJOSRqb2M/FOYQo8p4w6YKfMnuHqHfwA0oPuvs5wZa7P5wNnkGGNSmVAaK+WXOHL+9j ZsXvdEOXCLtSTZ8nVortc+KMjsE6skL7BGOKLtECY+/Z5w4GA7aybF6SfhBDVjnGrsB6gOxYVe8p FtjTzc1+njwhwgrZKY7YAT6nm53Es0FpgvghzY/A66bNx1DqElcAPKbzcxP4iEAXCPHiNMpjATqM 4D6o9UmMrAKm3oU7Xjfc8t9V9hjsyxcWjSvsS5DB15aBxG7KvNc2M0StCcqAmSHoMlzpFkQs95ci qrhqsbVTbmlv2tIN0B1ZTU9C0g92QDu9T/i/632gw3j7l28cm+3j9DtuxVayumancyiZHO/0N4dw u13NkPEF+fSbmhFap08w1JH9jHXb09z2NP7/fU9zaD/fdjKH+o3bTsaHDuO2k8kPVz5OJ1M2L9DX qAOP7KBHH/skB099loTSqdxQfCL0wY+A3zOLCQwqOX3miYtTwFUMj6rMwQQWLuJIy3icyd8QGU9j tILTobqvlEQiVx0Jb8UEHBrpYaduhafr5JQtssPOel0dbGaVVSBZjtfCYhwOqmSGbrXLA7xCvWYb 6YPWLQElex0SxmQ2iaaDRHs7qIykj3XBaA4SemUfhUXXwaKj1G9dtccCqBVegR/cHvxM7/lhACIg BOdx0JwvlJ8yV2+9q535MT19yJhWBECDvY2A0tNdxfXg8tTqslC7gqctEka42SS0ZXSDJ2L4GZxH pxq9Co3r+rpbutSip0yh54PQKmm0O+9jcVNfg9xubqCpmSlo6l32/FYzhJCZo1XPX8KhMTwmK4gd oX5zIRrB3ctc8mzD3ySzrLiQIyTizOA66WTZICESc4+SpOer5RduoKnOIZpbvQEJ4ZMl14W08qmR A6fbTsbLJZ5L0+3GiLJ09goZPssVzm+1+M3BSpKtwd3TeHHpndE1f4ogxMJ2XRlwQQTcHdQzay4I XIYViayMv53ClKdd8zZKx1A2jugqRnlFMZN5BtepvKCj3wobGG/5msGghknyQngWqQJrGtWqpkXV yDgcrLofFlKWM5JmWTOtrKKqpjuLWTNsy8COLW9W5A1WWxNDTjMrfJa6d1Nud5vrdvqEokqAwQv7 OaruFQqCQa2czKKmGO+nYZWz81G7dmwX+AFqVykSRtZvbdXu2K2oEc7pYPBGlR/kdqMWhpbbvlJb Wt+bmxfb7OwFJI8RdLlrKoV2JVxbcwQN0VT3JFnagC3yUuZbA568NSc9/8ta2A+GjXBYqXXCcSVo BrVKJ+w3K/0wbNbHYb02GjReQWGRcVIPszv7CVxg0E1+c6/H927vk+0dzZ05S6pM38pXNXF9e19v WLf32U28N1OX875HIOl82WpMus3uoFXpNvuTSjAadCrdYWtQGbWG7dFkNAw73ckr37vQ4KDfHAat cafSqg+HlaBVU/Q73Uo7aDT6QbvfGQf9V3kbAyvP0kduCzCv5nXvvwAAAP//AwBQSwMEFAAGAAgA AAAhAA3RkJ+2AAAAGwEAACcAAAB0aGVtZS90aGVtZS9fcmVscy90aGVtZU1hbmFnZXIueG1sLnJl bHOEj00KwjAUhPeCdwhvb9O6EJEm3YjQrdQDhOQ1DTY/JFHs7Q2uLAguh2G+mWm7l53JE2My3jFo qhoIOumVcZrBbbjsjkBSFk6J2TtksGCCjm837RVnkUsoTSYkUiguMZhyDidKk5zQilT5gK44o49W 5CKjpkHIu9BI93V9oPGbAXzFJL1iEHvVABmWUJr/s/04GolnLx8WXf5RQXPZhQUoosbM4CObqkwE ylu6usTfAAAA//8DAFBLAQItABQABgAIAAAAIQDp3g+//wAAABwCAAATAAAAAAAAAAAAAAAAAAAA AABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAKXWp+fAAAAANgEAAAsAAAAAAAAA AAAAAAAAMAEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAGt5lhaDAAAAigAAABwAAAAAAAAA AAAAAAAAGQIAAHRoZW1lL3RoZW1lL3RoZW1lTWFuYWdlci54bWxQSwECLQAUAAYACAAAACEALS4A vJwHAADLIAAAFgAAAAAAAAAAAAAAAADWAgAAdGhlbWUvdGhlbWUvdGhlbWUxLnhtbFBLAQItABQA BgAIAAAAIQAN0ZCftgAAABsBAAAnAAAAAAAAAAAAAAAAAKYKAAB0aGVtZS90aGVtZS9fcmVscy90 aGVtZU1hbmFnZXIueG1sLnJlbHNQSwUGAAAAAAUABQBdAQAAoQsAAAAA ------=_NextPart_01D7B08D.18DB6DF0 Content-Location: file:///C:/ACF69CEE/1112HTMLEN_arquivos/colorschememapping.xml Content-Transfer-Encoding: quoted-printable Content-Type: text/xml ------=_NextPart_01D7B08D.18DB6DF0 Content-Location: file:///C:/ACF69CEE/1112HTMLEN_arquivos/image007.png Content-Transfer-Encoding: base64 Content-Type: image/png iVBORw0KGgoAAAANSUhEUgAAAfgAAAErCAYAAAAygpH+AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAO xAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX/tNXEAADLPSURBVHja 7Z1NyCzXmZgbqmjXVN++ut/9fHVvBsmKwAgZ/yBjDMKEIBIIHpJxxDCQbBwyCxMzExMPIYxtCJZh BmnheJHAjRcKXmhxQQbBbByvJLIQ2ii6CyMGjMgQpKCFJD4JxY4ZLSpVXXWq3nPOe+qnu6q7uvsR POi73fVz+lTVeeo9deq8ix/96EcLAAAAOC2oBAAAAAQPJ3kSLBb3czIAOEru044BgoeQ4DPqAYDr FxA80EAAANcvIHiggQAArl9A8EADAQBcv4DggQYCgOuXegAEDzQQAFy/gOCBBgIAuH7hhAV//fqN Z9br6/+H9033y8XF5cv5/x+ngQiTxkrdRVEWJ6tRftN6tcqSqNxutFydREO6WkZVPSXZarXO9O/j LFW+26oO0ySLY31fu/2OOIs2xzzKktTednHc0jjafG+O2ypplo/zzzbHNo69dRE8nIXg8/+S6zdu vPkn3/rO//3lK/8z+/XbH8Meufv8veyhhx/54OLi1jdoILqEVTbyZcPeX8ibRn6ZZl2Cik5I8PVN yx4EX9ZdNLpE17ms7Zu65resV2kWbz7Lf0NaHrN1kmxu+pobtvL3TVU+BA+zF/yNi8v//O/+w3/8 f8j2cLz+5jvZ5a0H388v4js0EN2Ctxr4Hg33Zt0YwU+5nynqbbVMcnkXgjbHuhJ2x2+rlxfHfHMO TFwXCB5mJfgieo/j+BMke3j+7Lt/8clymfwlDUQ/wReYKD5OqkY/jupor+6yXUZOBKgvVws+qrp4 KxmEtru5wYhMdCluPIquatPd79xUDFmn6/dEy3TTPW3KmdbLNr0cRoJmO36dlMJsuvPjLHaWdcvh RdJOdNy2LevGQ3tk1SLgzbE2dVMdq+IxTVlnSmTv1P+xR/EIHrYR/BOfeeTRDxHs4Xn+hZeymzcv X6OB6C/4RnarrOzOLb8vxW+iPTuaCy4nInjr79DyxefihqGUarmv8tlv9XfSlHfIOp2/p9hOUc7i //WyTTRtd1P7Ea+9zfCyst7Dx0D2rLTvd/teAvcmQpbJqee0uZEynx97Dw2Ch20E/9QXvvTlKwR7 eF548RfZxcXN+zQQ20XwRgTp0kTDuuCDy0mpuzcFoe1GZfSYGrm5z4y96HXYOn1/j5S13kVvP5MO Cl5Ztp/gm+127XebCL58tq7fVITE7X5u6g3BA4IHBD9zwTeisLukCxG0RvCh5QKCDy3fCDiuu36N rNsk0nedvr+nkbUt3rEEbwu5HJne67gE9js8ek+zREg6TewbjaDgRf0RwQOCBwR/JIIvJek8K65E WYyiTqKuLnplOaWLvukqV5YvXsdaptXzb+fGwDy/z5dJnC76vuv0/T3yN5ntJXIk+c6Cz/fXMkDR fbY9tuDtVyR9qTf7b/abmmVaxgogeEDwgOBnQJ/34OtGv+j+rm4GTPSWisFeoeU2A93MwDU52C20 fJLkIq2e9UYiqq/fw1aiygHrhPbbDJBzH1c0g9usgXPFTUIcW93/7sDDtO+yJopP/J4CbVCju63t burkvrU6a3oV5PKR804+o+jhLAX/+S/2E7z37Ky6WMrvmpGrxcU/lvRS8Xyv3o8Ybex+P/b+EDyc O/LaDj0rn3t0zHvwgOB7Sd5+H1V+J0ezbis5MyFJSLibSM5EHMXrPzsKuWt/CB7OneK6jpzHAZHS ZT/VTHa736Awkx0g+J0F3zwz3F6OZkKSYIQdL0YVcNf+EDycfQQv3tHf9JwVN9hH2s2N4AHBDxB8 MwlGVD9vM4J3J+9oBO1PglF+F1nP2pLQZBzec0PRhS8bo8gto1uW9v2VNwD2c76u34DgAYDrF05C 8LJbXv5dj0J2J++w1tdHMZuIeh18XSf07+Y9114TlXTtT/RIWH+3/IZTErz7elTivre9eQ5b1MUE c5AHtuuOAzEDt6xBeAMGUq1byl+eH+HR36H60bbtjujedwQedUzTO/z4yN/uvH9vritRJ2k87Byx BsttBvoN72LvOn7HVu8IHvYuePn+rSZEi807xfKVoJEF3/KIwJ4wxH7VJrS/0Lu2bb/h1CJ4bTa2 IQ32Ng1zI+zwPorv3TJtnhUPHKnt7seUd93z9S53hrW2OjzECO6pbizkcTXjYuppfSMxQ1/9ef8b Qbm9RvbDbhDWI7yeN7d6R/AwG8HLKUTV9ScUvLpPa8KQ+Qo+juOPp0xNu11jHvlziS/7RSZDI7e+ 4hxL8O5+ZHnL47y74KcUbfdvm15wMlLeXIPOBDzNLION8Nu3pfSG5Nt1j3e/m9P9C36qekfwcOAu +tjroq/v7NOknLxjSsHXXYNxnYGqmPCjKWNqz3y2axf9GUTwWlenOZZeN3TVoCbmxmjZ9OIUdR+8 MbRew5LHdjfBN2MlZBQZ3o/sdWqOc76c9UhCe2QQ6OJXuuiTuOnNkhKq6yzVyiiX8d8Jt877lTPv vTU9b/vvaZ1Ctm2iGyFS9xhox6RN1H3eVXe77/3P7Xpzf++QOtfqyj2vvPoYWO8IHmYheP09+Ga6 0HpSi0qYzQA1ZZBdcWElSf29nBK0z2Qc2r83iTHkhCFxMzOY/d68m4xD399qZU8q4g2yU37DSQre mfJzk8LTauzELGIyY1lxgxXpEbEUo5GA3b3bLXhNRHJWO/l83hzftv3o5ZWPlkJjAvRyar1Fdda7 SM5QZ08SY5fRX0Zuq+1RiJSrde22/J5tbwBjp/whwXf1snQJXvaEeLMNVlL1Zgi0fu+wOnfrSjuv 2nq8xqx3BA9bCZ6Z7JjJrrMRr7OgNfOCu4Jzu0Rd+YUE7zaEjQS3j+C9GdCceei1/Qwpb78IXmzb 6aJvpOJ3I/tl9JeRIgxNJes/Wmn/PdtG8MXYFvd3TSV4rUeg+Ld2PoR+79A6d29Gu+plaL0jeEDw CP6wgjeRR96Y+1LYTfBrJ9XpWIL3GvyO/cxB8HoZw0Iyj8a0/U8lGncfXjrcwDP4PoIPPoOvHguZ eSvc7e0i+K46dwXfNRYAwQOCh6N7D16LrrYXfPNMPo7druvdBS9FYyLctGM/YwneSCAkeG3cgnzk 4ZdRHyy27nimG3wWPJLg7a7osmen7aYmdNzURxsySYwcjS9uALybRKdHo6/gu+rc249zXu2r3hE8 IHgEP1kDIZ+1WtKvJJMog4/cfO1y/ELkDW4rPnMmHeoYCNb2HnzzmT1osm0/srypGBC3UsoT7tJ2 JmayxqoE6iOyx4vIMsYtg7rahOmO5u76PUPwx0CIGyPlPXhP1GLQavf2lccTTj2651Yz54X/e5Mh da7UlXte7aveETxsI/gnP/vY5xD8DHj+hZeymzcvX5ur4GFelDM09nntLD741LLqM3/xNsbJHZsJ 6p3rF7YRfBLH8ScI9vD84IfPZWl67S6Ch14S6flu+BQz2Q2P+H25R0ecurW35JnJDg4p+ILLy1sv Pfvju3+HZA/Hr956L3vo4Uc+yC/ixxE8tMuye2Q7nGAjzvUL2wg+/+/Gxc3L/43kD8Orb7yVfeWr X7u6ffv2n9JAAADXL4wmeCP5IpIvTqLPPPLoh8XAO5ieJPm93yVp+lFe71+ngQAArl8YXfDOifRE Mboe9sKNY28gts0eFhyF3tH1POXz267XmKZ8nu3OjNaWsc0gX1Xbdt7/bevDPCrYvIe+bJl9bqKM g1udW4uF8o769GUb47xB8DCK4IEIYBsB7JI9rE5IIpL6hGUxXWa2tix2U95YyORMzWd6xja3LuS7 6GPLKlQf8r3zPvPHHwr3NcL6lbiRb9LasiaOdd4geEDwsF/B75g9TGuEN1JpS25ygAh+H5nZ2mZ5 0167SuPyPX4vIh2xboL14R735XEIvpH82DdCbbMZjnPeIHhA8LBzAzFkTvJds4epNwWbqDQJZ58L ZWarPk/lZCI9s4HJTHLBiHXizGytgndnCRRTt7rrhKdt7Z8xrbM+RCKXUG+EvZ/I7o1Qsrtp5XC3 FTp+gwRfHZtmquBANkQ5WU5LmdwshLucNwgeEDzMJgLYNbmI1WAv9FSq3nShPTKz2ZnE7KlG3Wxg Vj7zwFzo+8jM1hXBx3L/cdM9HimzC4Y+65UxrUd92DcNYhY7JaubdXPm1X/amrnNyxDXI5vbEMG3 ZUNUzxWlTG4WwqnOGwQPCB5mFcH3FbwW5bcKviNxiz/HvEnM4mcD8xvhdsG3lW2qCF52ga+TJuFP X8G7ZepKqNJVH37E3kS8ulDD2dhC5QjlGxgyILM7gg/PUa/tq+v3dR3TXealR/CA4GGvDcSu2cMO IfjWJDUjCX7MCF6WOXTj0HVTNTRjWld9uLPomWPYR/B9s76FBB8PmN626xl8l+DddRE8IHg4H8GP lD2sW/BN9rm0R2a2kOC1bGBlgy/X819LmzozW59o3GRs61pHq8/BGdP61Ed9DJz69bK6tWdjay2H u60e2dza6sI8L9duYNQ0stq50vL7um6AETwgeDgawW8arS2zh4Uyw7kNtJd9riszW9WVagYxpT2y gbnjAPQobZrMbEbUrRnyAoPdVj1H0W+fMS00eKwY5GeO+8LrxZHl7crGlvYqhzJIryWZS9sjEreH qU82RP1c8cs05XmD4AHBwywaiFPMHjaXzGxD6hxO57xB8IDgYRYNxKlmD5tDZra+dQ6ndd4geEDw QAMBwPULCB5oIACA6xcQPNBAAADXLyB4oIGAaQnN5qZ9rk2pynN7rl9A8EADATNDy0AX+lwOcrSm oj1AKlfg+gUEDzQQ0EPyodnv+iYBGjsDHXD9AoIHGggQjDl//dAcAX1mHASuX0DwQAMBM4vg5fSz RuhDkwIB1y8geKCBgJlF8EbqoWlvETzXLyB4oIGAI4zgrRsJZVY1BM/1CwgeaCDgiAXvdtXL6J5n 8Fy/gOCBBgJmIvdQPnj38/odeC3THKPouX4BwQMNBJwWZKDj+gUEDzQQcIIwkx3XLyB4oIEAAK5f QPBAAwEAXL+A4IEGAgC4fgHBAw0EANcvAIIHGggArl9A8EADAQBcv4DggQYCALh+AcEDDQQAcP0C ggcaCADg+gUED50NxJWaihQAjoEr2jFA8ADnfSP3DPUAgOAB4PQET1cuAIIHAAQPAAgeABA8ACB4 AEDwAIDgAQDBAwCCBwAEDwBUAgCCBwAEDwAIHgAQPAAcWup3ct7NSYzg8/9eyXma+gFA8ABw3JK/ l/NsNa3p0zn3qRcABA8ApxHFm3wDRTT/JPUCgOAB4DQk/71K8D+jPk7quN4n2Q4I7iN4oDECOFCj O/I1xcBJCJ4PVAoc7OSDvdd/Qj2c1nnPNQU7Cz7/7/Ei1eTFxc37sB8euHHj53mdf5uGDoDznmsK JhH8xcXF9x96+JEPvvPn389eePEXsCee+8lPsz/+F//qNw9c3Pyb/KDdoKED4LznmoLRBJ//9/Wv fPVrV796673s129/DAegkH0heRo6AM57rikYTfBJmn706htvIdoDU0Typ9BdT2MENLpcUzADwRfP 3W/f+f2PEOzhufv8vezi4vJlGjoAznuuKRhD8E994UtfvkKw8+imLwbe0dABnO95X4zFqSYqetaM y9n3NZXG5at/0XKVpcskW63WW+1/vVplSRRlSbrO1qs0ixfl3/s+NkP3Lcs95rIIHsEjeIAzP++r WQn/ayX6b+/zmloncbaISqmvllH9d/HdahkPEll5o3AYqe9SjiHLH+I3IngEf5QN3TFHDvvYz6DI Ik2yaBFn6Wr6hmebfbXV176jvbL8u+2vmuzmmQkn0rmxN8HHaV0P8jpM42F1dIjodoxyEMEDgh9Z 8MceOWy7zyG/rWsfZltlo1MsO73gh+yr7bfK7/Z5/Mqbid33N3aUXbzdlPO3VRKh/UXwpj6E5Ovr s7rZiBNTZ+Uxd4+XXNZ87t60mZt5c50351G+/WWapcqxsNeRyxc3aGVgUJ5LUbXvsnyNhIeXWytr 27IIHhD8CUYO2+5zyG/r2ofcVtmg7imC77mvtt9ql32/x2+sCH6k66dI+fvfc4q5MZ6a4uZhm5ue VS5HeUzkMbd6zERvjqxXKdPiWjcyLj4v/rY/84+Fuk5dhrxs1XeyHWmWc3v0+pdb3W9g2VkK/vNf nEbwxQ+PI3Pnk1dGmldmXDbah5ZpurnDKw8Qgp+J4GcaOYS+17fTftfvRRbWb9stWnC3VTdk5vO6 nOXnyaYs5baacsmGU69nWR/Nb9H31V2+phG1v+uuSzWyE+dP0/Ca32KfW/7vmJXg/+WUvQP9e5ci 57h3C75YxwjRFqu9jPX4IT8u5fEKH2Ntnea8am4ui3PBXEvhR3b9y63tN7Ts2QjeNBBFJZT/XpWN RITgEfwxRw4t25FlCezHjSy837ZDtKDXU9V41jJtpFY3UMU2jfyrRta6QVAawnKbbqPp7ssuo1s+ eVz8srfXpRd9W+U3NxwL5WbK2b8liXl10R9K8EVdSEEaYY4teFfCrsjd70PrrJPi+C+sc2RswWtl OW/Bp80zkUb684ng6aKfp+DnGDlo36vb6dhPV8MT2m7fxqRvPbnd6XL7evfn2rt50QXvL9tePv0Y 9Ymggo94pNCdmyGr29W5CZlTF/0cBO/2bnULXvT4iIjaHp/hn0P1dorzKRe1dqOrPcKr1ymOm3su WuWvlgueqz3KrZY19Bv3I/kZRPCi+yuv2KJr0xW714VvdVlWXWuRfcGa5YuDqm3HfN506eV3o3FU RyzFd243aduy5fJx2cA7jQyCH/8Z/BwjB+17bTtd++kr+G2jhV0EL6Vp9hdeX1zbsuGbUPChY6L3 VPQQvOipQPB+RJwkSdPmyXExceBxUl53kfZIRTx2qdvdSr7NMqbtLyNx+Vn4UYy5YdBv0mW5rJtE 5fuucvv7bV/2jJ7Bp43Aq8qM6y77pgvfjfblq1Irc6dkLkjxfHDT+Ic+t54h2ndYa+/fLctWNxxN F+x0jxkQ/FwjB/97dTud+2mPLIJRSs9oYVvB25Ftv0jHq6MJBa/ViXfjpd1otEbw9rWM4OGY29iD CF6KPokje+BTJc6iAfeej4tnc/U2rEFGols09LlpkKzXKToEry2rCX6iZ/cIfp6RQ+h7dztd+3HL 7ZZ5jGhBbqtep+rmN2VLWgf/LbxeFLee62hJDMoL7ct95CHLF6qvPsdMfYQiKXrjIiXaW7hSb3oZ o8Vu3awIHs7qGXwsurmNpOsBPEKcfQRvLnh3+dDnYwne7tIvGw5ZLgRPY3RuyB6NjbR3mJDolBtd rik4acGX3e7Ns/fiWbY9AKYS6SYqyKP8ZBWO4J1nLMW/E9FF730+VgS/+fd+RtsXgo/j+OMJZ8La G1yEJyp35TFA4nTX0+gieDiTCN4dSGdF5UkzeC2qRtdbXe7Os2452E0OstM+t7pCnW5fOyIXXZbK sqHuvymieCJ4OI4IPnbegSd6P2XBM+XxsJvesxD8qeBPhsEoegQPcNqCZ8rj/sw+2QyCbxG8GPks n/trYwcQPIIHBH8K1xRTHp9QBM9c9Ex0g+ABEPxGWGc65fFam/2wpTwkmwEEP3VjdIBED8eInCNi 39HW7l22fgMabozd1wmLuTj2M8r/VAR/rlMeNxM8mXXsCZ2sG4kjSjZz59r1B36DYA/Pcz/5afbA jRs/R/DDpLXN3bM7a94YUc8+Z7Kaxw3DtI2a9yy1I33wOpe5vNlIY9kAT9/FfDIR/BlPeWwllkqG z1s/O8FvDsy1a++98tqbSPbA/LN//sfFK3L/GsFPG8HLWfLGjDTPSfDatLvTH2c/Uo8Cr+jJvBd1 d2pgDnsEP57gj3rK4zrhkJxF8wQEb7rpX3/zHUR7IO4+f+8kuuenbIxaU4KK1xtlo+++Erlyn/vV r0Lm21jG/ixwbopR7zVOf3tut5/72qe+nbVaDvmapvxd2udt6VH9edhb0qgqs0N6+5a/pWN7epf7 olcCmdA+ZR1okjev6YakgODHF/yxT3ls575oF/zRJJsxXL9+/ZuXtx58/5t/8m9+950//34G++Mr X/3a1c2bl6/lB+0Ggu9u4P3nX/70o+7FuZFtkorBQW7OAkeGwX3ZDZXchp9IJrB/dTtKObxGMtR4 OnL10qPKRxntaVTdrnc3KnM/W/dIyzrWIxBV5IFxAFoX/tS9Dqc1iv4MpzwWic6iSthxS3mOItmM s9KdnO/mPAN75eun1H07ZWPUlRJUPvuTDYEVgTpCDnXzu/tynzGGtqc1RG6vQijq9JOj+I1I++dt 2dP8v9sirzbB+70J3alXt43gN/XbMlDOPGsPdc931TuCP9A4DqY83q/gAWYbwfdMCeoK3o4y/ehb FVRgX5rsugSv7T+4HVWUoeQqoc93E7x/Y6FFx9sJfvtoMtz1KaeStupbqV8EPyO5M+UxggcELxvn /ilBG5En1qhe+1WckOCH7MtNU+yKXd1/aDvejUYZ8dbP2KuR+sHPR4ngu18rc29QphS8HBjlPlc3 vz1SPgv1ptBFP6cInimPETwg+B+FUoIqg9zkoB/3vWgl/ewiTsT6biKkhT8QLtAoyWeHfuTeNZDN SWfqDVxS1nc+X3vry/SosZUPoj2Nqt6NLsVojVFo3e9uXa7uM86FMpmJ1hOiRfwMsgMED0BjBIDg AcED0BgBHIfgtVcNz40pJmja1OvEcywgeEDwAAi+RWzDHpu0ZWwbwljbmeUNw4FumhA8IHgABL+1 jNoytg1hrO3MrzfAf4MDwQMNHUxV789QDwjeitjdwaNyghprQqVqMOUyzVI1K5ubOc7ffhmtR8qk R8pATWWf6vpKxjotI5z7WXsGPGeGPW+Z8MBdq46d6Y/XHZnwdpnJEcHDnBq6K/UkBjhtruYieD8z mjvLo5iO1cqy5mdlk2Iyy6nbF8Izc1G42d2kHN19+uunfsY6JSOc/1kazALXZJ4LZ4rTsty11bEn 75ZMeETwAEDPCex8bL3MaE4XfS1pZ7rnZl19PvrQ9rV5BoLzySv71NdXEto4ka/2WXuCm/bMdVqW uy7Bu2XV1iWCBwAED7t30WuZ0QKCl8JaWBF+WPDa9ocIXttnX8G7y2if7SR4JcvdGIInggcABA87 H1s1M5o1QZF4Fi3mhDfd3V2CV7dfSF9uvyUKVveprq/cWDgZ4dTPdozg+0xpHHwGj+ABAMHDtBG8 nRktdbqI6ymAi1TLUXh2RiujnDejo9y+zLDWyE1uRwq+bZ+9BtSp6znlcLLApVo2PDdTnJLlTq1j ZxR930x4CB4AEDxwbA/AkCx3ocRP+z4fOHAASAA4ttAm9y2y3DGTHQAgAeDYHkUEP/8sdwgeAAkA xxbO4HygUgCQAHBsAcEDABIAju3hcCfSkd/Jd9BPda57BA8ACJ5je4Jyr+a6Vwavme+aaWKnnRYW wQMAEgCO7UiYeeb178rkM94scmeU6x7BA5zHhX4n592cxFz0+X+v5DxN/SD4o4zeq3fL49ifLrb4 LknKhDDuDYA21S2CB4Bjv9jv5TxbvdrzdM596gXBHytlNrci7aqZTlZMixuXUbomeO0zBA8ApxDF mxS9RTT/JPWC4I9Z8FLUTVrYZoY5BI/gAc5JAN+rBP8z6gPBHzNuEpdS3KmaatXNhofgAaY/+e6r OY8BTpv7+2rQT1rwMtNdICsbz+ARPBBtnFu9J9TDaZ73Z/eanJguVpP2ilH0CB4QPACCP/WIf9rc 6wgegMYIOO8R/AFgJjsEDwgeAMEDggegMQJA8IDgAWiMgPMewcMxCD7/7ynYG4/T0A1DZplqey/W X0++fjP/BBVdZTzlJBtdA6dSM43pjH4/gofZCj7/78bl5a2XihW/8KUvX8F+uH3n9z9aLj/12zS9 9i0EPwz3vddinuq4RfClFEohyL+1ZVfLeCtxbLveNut3/YZjpu23Fa9QzXFCEwQPsxR8MdVlLve3 n/3x3b/79dsfZ7BfXn/znewf/5N/+tGtW7f/CsFvL/ghUWF3hLidOHcd0Ttk/VN+Pajtt811xjIE D7MU/OWtB3/5n/7Lf0PuB+RXb72XPfrZx97PD9wTCH644M081XUe6UWcpSs7Uu8reG2SjbpLeDOZ RvOIIF4Wma/MXNnhyTmacjVlKz8rU19uyri013e74DdJOKz17d9gl9F8b8qZZqn2W9Vy+euFttVn n33Xdetei+CbOmjWk5/ZOcJF3e7hJgjBw+wEX3TNJ8nv/Q7JHp4f/PC5vPG7dhfBD+nG9WVgGndX gn0Fv0pT6zvZJVwnvqj3kS9bfeeup0WdzX4b6UWB9a2bEzE/d1MG8Xu0Mlqf9S3XWl2v+7PwPnuv W6UJ3Ry3zd/dEfxmOXNzkZY3W3Hi1y0RPJyr4J/87GOfu0Kwh+eFF3+RXVzcPPpUn4eM4McQvPud FTWK/NRltFnup0+XuRXJJutMllNbX/5bexwhv9fKaIS36JjC0yuXsp72Wd999l3XEnfPLvpg5jGn bhE8nKvgnyoGeyFYBH/Mgve7nfsL3u3i1QSv7icposdFLymVNwNN5D6F4EPjEczv03+DX6629eRn Q/fZte62gvczjyF4QPAIHsGfgeDlM/ntInjZPb7ZnolUi//33KYpq4mWhwp+U4b6OXdVBvd7t4yy VyMw8lwtl7Ke/lm/ffZfN1bGAfiS9rro1TEWCB4QPIJH8EfXGLnvwYfEZZ7NR26knosyFX9r3ddm fW+QXX2joHdJu+vZkbIpT7mdWBlkJtdfOWV03/0Of19JsuphkJ/pEbxdrlRZL7StPvvsu679WVc9 LuwovnVQ5H4kj+ABwQOCBziDRpdrCmYh+M9/cXzB15GNh/vcs7x7L9Ypo6rm3200yzav+RR39OHl dt8ngqcxAjiQ4K8WC332RjhLrg4q+I3knXeSN12rsXxeNobg1/X7x12C77PPzTLLFMEjeADOeziO c28Ogre/82W79X5aBD90n2ZULoKnoQPgvAcE30vw5YQgIdlq3efFvNxeN3/1vqw9iKcSfBTXA560 bXbts5iEQ+8OkY8Cyh4IBE9DB8B5DwheeUbuytb7t4jK6++86TCVZVMxdWjXPtx/m3EDVQTvjpBe FzONJWsi+DNs6IZkorOWFTOt9dneFBnizCt9Y9eJmVTG2ldgut7mZlrO1Hda8+gjeCCC30XwfZYV kt5V8HWXfdVYpct001Aj+PNr6LbJ3Faf/x2varVte9fsdKEbjF0x14UUvD9tbHNdxcrENKeW7hbB wxkLvhHjKu2WtpRr+T5rXHeN71PwTRQfTxq9I/i5R/DbZW7rI9j2CXK2F2C53ekme3GnidWmjdXe Y7duCoo2Yo/vqnPeA4IfXfDNc+tVMatVsu4pX30wXKvgq7/j3vtoF/xmpH282MurdIXg4zj++BRe 4ziNiN19LKR1qduT7jTjNewu+iR25rH3tqFs2+ruVrK+1a+itkxiI7rm69ndzHYdsfq/xZ9/f4jg 3X+bN1S0uh6S9hfBAxxY8P3fg3dmFjMNj7Z+FcV7KSPzBqvIIGUGyUWVoLv24e1zZWehsn7LHkbW E8HPJFpXs8fZ88Jb57EzbayVBa7OcGZPBxtKY2tt281qJ7bVpwvfn9tdJIUZoXvcE7iTfEc+o5ft gfvcfq753RE8IPiJCEYTB3iFrWicpu6eR/DzQc2SFkpaU0XJwe+dLno1PeuAjHebsjlz0vcWcCAJ z1gRvNXz0ZbP3ek5QPAA5yZ4kVxDDnjretd9TDaN1ea1vGTSwXUIfn6Cb8vc5v/tdr9PJ3jZC9A1 AG+o4HeN4K36Cozc1565I3iACQXPXPTMRU9DZ3fRe5nOWiJ471WxgODDz92H5axfB56ht/2OfQre 7ap3v9Oifp7BAyB4BE9DtxfcTGfBTHTOWJFCXnaWN7vb24gstL00kCHOFWAfKbqj6NNYmSxqyxHs 8jFG/Zw9cONhPfJwonpG0QNMK/gnPvPIox8i2MPz/AsvZTdvXr5GQ3dM0X5iRcHpcnpZlTkd+u1H vo8+u7oboReB8x6gXfBJHMefINjD82ff/YtPlsvkL2nojkTujqDW1WRO099UxIO6tKeayW73XhJm sgOYVPAFN29++sff/rf//mMkezhefeOt7Pbtv/du3kjcoaE7pgg+dt6Bn05YaRwe0Q6c94Dgg1H8 p289+D/+4A//6MO//uWrCHePvP7mO9nd5+9lDz38yAcXF7e+QUMHwHkPMJrg6wghvfatBx648b9O YSa1Y2G5/NRvLy4uX87/fpyGDoDzHmASwQPQ0AFw3gOCB6ChA+C8BwQPNHQAnPcACB5o6AA47wEQ PNDQUe+LZ6gHzntA8ABTNnRXvCEBZ8gV1z8geAAgggQABA8ACB4AEDwAggcABA8ACB4AEDwAIHgA QPAAgOABAMEDAIIHAAQPAAgeAMFTCQAIHgAQPAAgeABA8ACA4AEAwQPASFK/k/NuTmIEn//3Ss7T 1A8AggeA45b8vZxnq4QnT+fcp14AEDwAnEYUbzL4FdH8k9QLAIIHmEI490kdCmcKvSeA4OGkBc9g r/3XefEM/m+LaJ764NwHBA9AI3dikqceOPcBwQPQyAFw7gOCB6CRA+DcBwQPNHLUA3DuAyB4oJED 4NwHQPBAIwfAuQ+A4IFGriSNy3eVo+UqS5dJtlqttyrnerXKkijKknSdrVdpFi/Kv/f9e4buW5Z7 zGVNvS4OVA+c+4DgqQQ440ZuncTZIiqlvlpG9d/Fd6tlPEhMpdAOL7Oh5RiyfN9li3otbpj2+buH Hi8EDwge4NQFH6d1uWQEn8bDZD0kup02gh9Wjiki+OJmad+CH3q8EDwgeIBTFvymO3thSb4WfzXN aJxUyyziLM3l70axclnzudtNXndXVz0EpSir7S/TLFXEZK8jl0+yqHqkYGS6EOVrJDy83FpZ25YN yb1eVvaOLJpHIU3d51H35jt7m+a71OzX6llRtmUdr/lJHsEDggcEf0jJC8mscjnKSLUWjiXQ/O+0 kG31+ebv8nMpU9ldXXxe/G1/5gtTXacuQ142Kbbq5qRZzh0L0L/c6n4Dy/aN4DfrmBubtLw5iZPm hsWN9OXNT/Hb5M2Svq38BsI5Xpz7AAgeaOScyNOIcdVL8JbILLHay1iJRwppVXKSkWkwChY9DGWk WpbDSNiNWPsIPlRubb+hZfsK3u2u929Y/G31KXfopoZzHwDBA43cRphSkEaYYws+1G1shOp+H1pn nRQR7MKKsscWvFaWXQUvH4GY77YVvL4tBA+A4IFGzhG8+1y8W/Di2baIqJuu5eLfQrKiG32zbhHB 56KWz8K9bmptnSLq33RZO9uuy18tFxR8j3KrZQ39xvbn8FYXvdIzso3gw9tC8AAIHmjknIg4Saru cmewnRlsZiJa+V53FCmD0sQgr7qru5Jvs0wlrSoSl5+5ZbPXqcSqdO+775uH991dbn+/7csGb5qc QXCy69/bj/KYov6uekQQGrDn9r4wyA4AwQONHADnPiB4ABo5AM59QPAANHIAnPuA4IFGDoBzHwDB A41cgNBI6qlGWE+VUEZOLHOI4zTliHQ5Uc2+9ik5VAIcBA8IHhD8zo2333DPJQlMGyZRSt/X0LbZ 9q71OM4NUXhyn6l/m/s64j6T0yB4QPCA4I8ogh/35kR/537sbc81gt/Hb/NnwYsQPCB4gDk0cs1E LXaEG0qEEk4CYyc46ZMIRv9MzJEeSI5izaseeOfdTZTSlmil7d1xtYw7Jc3x67t+B1/Wv7ff8H6M 4JPYnnegXEZ5715NMmPmEtATzGjniZcAR1nXPw/CyXAQPCB4gBEbOW1a0mDSFPVzP8FJ30Qw2meN uMLJUczUqm1RsZ7YRkm0opTVvVFwy7hr0hyZ0KU5DnbXtlpfrfuRswU6NzWrcHIeN6lOKMFMaPpa a/pct168fabBZDgIHhA8wASNnBUtJu1zqutzxNvd330Twaif9cnaVompTfBD5r3XEtDU2+koY9e2 Q/PNb/brTIfbvd8WwTtRuTsvvfY7u+bc7zpPXMGrv9E9D0Z8VILgAcEDgm+T+6ZbtYmYxxL8kEQw 8rNegndSn4ZvWvpJuM80rKEybit4GWm3DUyz97ub4N3fOUTw2nnSR/D+9hE8IHiAvTRydqa36u+2 pClqghS70e6bCEb9rGcE39XF21fCWlltsbWX0d92n6Q5zvN57dm/ut/AfmQ+d20MwyqUnKc9qU7X edIleHWfCB4QPMA+I3iTNMUdxNWWNKX5XBu81ScRjPaZTIKShJKjpCKRTcvzXJkopS3RipYIRopW S2CzS9Kcrii6z37lftxBh2Z7rkzbE974ZbYG2WnniZIAJ1wvznk1wqh/BA8IHhD8iSGj241EluO9 IrbX31GIOZ6u7GO/Gsi5D4DggUZuWik63ePJCCOyD3OjEk+ahnUj+Og4b3449wHBAyfbWUbwces7 8HMnjdsHCI4Tuc83jzvnPiB4ABo5AM59QPBAIwfAuQ+A4IFGbnS6sor5r3DNey57Df81vnF/w+ad 9gm67rVZ+pqJaCJvFj3/7Yn5HSsEDwgeEPw+xNfj3XQ5f3pXdrVts5JNnc1syix6YyeNcUUuj0+x r9hMMVtN/euWwZpqd4Y3ZAgeEDwg+D3gZhXrjn7bs6ttGzFOHWlOlRWu3O50Awbbjo+8OfOzwznv 1c9oVD6CBwQPCH4Pcm+yikVWZjQr61lPwa87s5LJTGvlpDd18pSW0eP9st71z643Vua7evuia74t +11zQ2BPohOaT79N8JvtLNMstFyb8Dn3AcEDnFkE3z6HfLfgu7OSyWlbm/fgQ5nQXCG2Zb0bkl1v rMx3fv2FtzdmBL8WMwLKOnFnumsTPuc+IHgABN8/gu+RlUyTUZdE+2S9cwXblnxnrMx3mjhD2xs7 gq/rQZ1m2B9vgOABwVMJgOB7C16KNpRzvG2+9lCykz6C97KdDciuN1bmu20EP0YEb+1LS3ijjOhH 8IDgqQRA8H7Wsy0jeDUrWSWfIQP31j2y3g3KrjdS5ju3LHsXvFJGt3fEwDN4QPBUApxRI7duySom s57JLG6pk9HN3WZ7VrJKskb0SmY4TUL9st71z643ZuY7dxR9W/a7beTu7t96PCFvLNpS2DKKHgDB A40cGGH2z3wnB/PN7ndM9Hog5z4geAAaueOT+xaZ76aayW5XmMkOAMEDjRxYEfxxZ77j3AdA8EAj B8C5DwgegEYOgHMfEDwAjRwA5z4geKCRA+DcB0DwQCMHwLkPgOCBRg6Acx8QPACNHADnPiB4ABo5 AM59QPAARSN3paYMBTh9rmgDAMEDANEjACB4AEDwAIDgARA8ACB4AEDwAIDgAQDBAwCCBwAEDwAI HgAQPAAgeABA8AAIHgAQPAAgeABA8ACA4AEAwQMAggcABA8ACB4AEDwAIHgABA8ACB4AEDwAIHgA mI3U7+S8m5MYwef/vZLzNPUDgOAB4Lglfy/n2ULwhdhz7lMvAAgeAE4jir+qBF9E809SLwAIHgBO Q/LfqwT/M+oDAMEXjcLXLy4uX15du/Ze1TjAhDxwcfNvHrhx4+f534+fmFzuc3wBanhEAocV/K1b t+995atfu7r7/L3sldfezH799scwMS/+9cvZcz/5afbQw498cPv27T89IcEzensexyGhHrge4MwF n6bXvvUHf/hHHyLdw/Crt97LHv3sY+/nDcETNGgACB5gNMEnafrRq2+8hWwPyPMvvJTdvHn5Gg0a AIIHGEXw+X9//+blpz9Gsofl9TffyZbLT/2WBg0AwQOMJfinvvClL18h2cNzKg0BDRoA1wMgeEDw AAgeAMEjeBo0AK4HAASP4GnQBGlcvpccLVdZukyy1Wq9VTnXq1WWRFGWpOtsvUqzeFH+vd22tlt/ 6HqyzGMtu06TLIrT0Y/1ZrviPfLieHnfR+XxS+Pt6x7BA4IHBH8CDdo6ibNFJYXVMqr/Lr5bLeNB kihvFA4rlqFlGLJ8n2WlZMf+bZvjUwveLkd587Goj9+uN1gIHk5e8J//4vSCry9Mc+FWF+jQ7TQX f5ylPdcvG4Fyv3GyHn15BH8kghfRpozgh0aBQ6LhyX7PwDKMGcGX35fX3yS/axnuFShuxiLRftS9 GRPdbCB4QPC9JW/E2V/O4RuFYdswNwZ9hT10eQQ/c8Gbc8/pUt6Iv76Zs89PN5KVy5rP3QjSPAZo IszmxjbOxZU60pTrl3/n+zb7sXoZ7BvbRsLDy6yVs23Zrpulumy59OM48rrVvZv7hX+jb/UMVPuP 4sSqr6J+CvnLCF72OhTXKtcDwBkK3jRefYU9dHkEP/8GrTn/Gnmt0tSKVmvJWhLN/96Ip/p883f5 uRRqcc4YsRWfF3/bn/nSbNYXEszlaYlfCLXerjcOoH+Z1XIGlg11oesCL9ZfqQIe1NNi3QSIm5JN r4u+fbdMXA+A4A8s+CaKsO/86+XzhiaOmmVSKyJyt5Ff8HXjIJbdbDfKt28LW267GChU3zwElt+X 4E+AV+beoJURp5HjqpfgpUBsudrLWHVRiNpEpAHh9RG1Fp32WS9UZq2coWUHCT4SAl40XfhDIvgm ki8GQpbd8eWNUpIlibj+ETzAvAVv/9tuGMx3TXQhIxdlG0rjIrvZ5d9me/Fme+X67jJ00Z9YF31+ 8yclaaQ5tuBD3cTyfJqD4N3tTSn4XW/Gin15NyXOYwAEDzBXwSsNQ6iLfIjg3e7TWvBeN2AZxYSW R/CnIXj3uXi34MX5ujkftF4kIVrRlb5Zt4jgi8hTPA/3Xvnq09Vulb3abnC9HmVWyxn6fUp07TyD H1PwpnclTsqb+bR4Dr8Kj6J3b9i4HgCOSPCyy34swZtowN02gj9lwRddvOL9ajmiPl5Y0XX92KcY 6BUpA9PEGxbNADPzXvbCfkxU7DOyP9Mi+2L9JLa7zPXtOt3syvddZbY/b8oUWlZ/rNCsJ6Nr82hL e3+913ES78AXg+zc7ntN8IyiBzg2wdcXerwZSbsuBkMlXV309vbtLvfY66Kvo6K0fL4XWh7B06CB JuJpXpUbVI4ZvLLI9QBnL3jtPfhERiVOdLV5VS2Jvbt561mciV7EazqRNRLZ7LMZNFdveym3nTpl 9JdH8DRooEh+gpnshsBMdgAdgmcmO2ayo0ED4HoABA8IngYNgOsBEDwgeAAED3AIwd+5dv2B3yDY w/LqG28V045+RIMGgOABRhF8weratfdeee1NRHtA7j5/L7u4uHyZBg0AwQOMJvjr169/8x/8w3/0 IaI9DK+/+U720MOPfJA3BI/ToAEgeIDRBF9w69btv/rsY5+7eu4nP81eePEXsCd+8MPnsstbD75/ cXHrGzRoAAgeYHTBVyfikw/cuPHzi4ub92E/pOm1u8U4iBNr0K5OJHEOwBhcIR04uOABAAAAwQMA AMDM+P9ZYbN7o2GdYQAAAABJRU5ErkJggk== ------=_NextPart_01D7B08D.18DB6DF0 Content-Location: file:///C:/ACF69CEE/1112HTMLEN_arquivos/header.htm Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="windows-1252"





                     =                                

https://doi.org/10.31= 011/reaid-2021-v.95-n.34-art.1012 Rev Enferm Atual In Derme v. 95, n. 34, 2021  e-021093

 

------=_NextPart_01D7B08D.18DB6DF0 Content-Location: file:///C:/ACF69CEE/1112HTMLEN_arquivos/image005.jpg Content-Transfer-Encoding: base64 Content-Type: image/jpeg /9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAMCAgICAgMCAgIDAwMDBAYEBAQEBAgGBgUGCQgKCgkI CQkKDA8MCgsOCwkJDRENDg8QEBEQCgwSExIQEw8QEBD/2wBDAQMDAwQDBAgEBAgQCwkLEBAQEBAQ EBAQEBAQEBAQEBAQEBAQEBAQEBAQEBAQEBAQEBAQEBAQEBAQEBAQEBAQEBD/wAARCACWAXIDASIA AhEBAxEB/8QAHQABAAIDAQEBAQAAAAAAAAAAAAYHBAUIAwIJAf/EAFIQAAEDBAECAwUEAwkLCgcA AAECAwQABQYRBxIhCBMxFCIyQVEVYXGBFyMzFhgkN0JSV3S0CTU5SGJ2gqGlstMmNHKFkZKVtcTS OGNzdYSxs//EABsBAQACAwEBAAAAAAAAAAAAAAABAgMEBQYH/8QANREAAQMDAgMFBwQCAwEAAAAA AQACEQMEIRIxBUFRImFxgZEGEzKhscHRFBVC8CPxB5Lhsv/aAAwDAQACEQMRAD8A/VOlKURKUpRE pSlESlKxJd1tkBXTOuMaOenq066lB6d+vc+n31IBOAkwsulY0a4QJqUrhzWJCVhRSptwKCtHR1r1 0e1ZNQRG6JSlKIlKUoiUpSiJSlKIlKUoiUpSiJSlKIlKUoiUpSiJSlKIlKUoiUpSiJSlKIlKUoiU pSiJSlKIlKUoiUpSiJSlKIlKUoiUpXytaGkKccUEpSCpSidAAfM0RfVU7yL4j8WxSPMRj7rFzcgu FiTNUv8AgTD+t+SFDu+96fq2/QbK1IA3VS5dzTlfPGbS8d4yySdjnHWJymzeMjgLLcm6SUnqTFir /wArW+3bp99fZSEL3d3xHjLNoqshy/AmordvdCI5tcpyKh9allxTXkg+USralOLCQo79dkVyKvtL wfh1620v3kEguOkTAGcxtPL/ANE6tVtzcUXVLSIGJPPw/vgv5Lz+68ux7NlN1y/J8JsZ2TYYgQhF 1UhWw8qU10yERyfdUjXv6OjrZMe5stOf37CHpOItWnKrnepYjoW4GApuMghbqemWE7SSG0dIPbYI PapmnHcYy65pbtWRy4kl0BLceZBHQhCR2SlTStJQlI7e6AAPlXnebA7k8llGJXWz3ODEaTHhxos9 vzUtjfdTailXWpRKj29Sa9vwjjvBbvQ+xuGETsYG0GMwScjnkb8lwLineQTVaT0jc9+JHywufeF8 EzW8ci2/jLk3imTYbJeS66qfbWH4hjSmmVrbeZkNLLKF+70kD4gdEHQq+MRazrHssk8UWXO+Q7VJ jmR9jSsqt7Nzgvls9QSmSPLW60tA2EK0pOtJcBGjucdt+UYbjOT3uVDuMSWzFREhtlCwQ46dFxI9 PdHfq+896jtk5z5Bs4S0/cGrk2jt0TGgpX/eTpR/MmuveNq31R7qYaQABvjVvInUNiAR81a3qtoM b7yQTny2jkeRVtYJyjd5TUq28gsWhi4QVFKpNqdcLLwB0olh39ayoH1RtwfMKPoLHjSo01hEqG+2 +y4OpDjagpKh9QR61zpy3dePcezGLGySVcrPPu8Ju5LmMNCRGbcUVJUFIGnE90b2kK9fSrDwLJmT Y4l1sqI+QtyZyIdxlWiUFpQCjaZKmDohY2gOJ0F6PUQQK8/d2dM0216OJ5HbyOx/uF0bW9earqFU gx038xv/AHdWdSvCJLjzmEyYriVoUSNj5EHRB+hBBBH1Fe9cjbBXW3SlKURKUpREpSlESlKURKUp REpSlESlKURKUpREpSlESlKURKUpREpSlESlKURKUpREpSlESlKURKUpREpSlESq+5Jyi5ouFuwn G22X7jc1gvoebDjYYOwUrSe3Sob6v8kH61YNQa2Yc6zmGQ3qZemHLhObCYZR3cjMK7bKD6a6QkH5 9J+pA4XH23tag23sgQXuhzmkAtaASYJOC6NIOwJkkLesDRY91WtB0jAOxOwnuEyfBaSJwlx7Gx9u x4W4zZocFx50R4SuuO284oqcUUqJUNq3rauyQANAAVH8gwa53j2djF59smwITflRozUkJe+qlrSr Q6lHue/0HoBUxvjTWD4qbQw+HJtyWoLcA0Sj5n/s0PzNQe1QHrrcY9vjnS33AkK/mj1KvyAJ/Kvj 3tNxejSvadpUtAbmqG+9DXkHUT2WA9oTEF2CCdPRbVGxbWontQwbYxA7voo7lFvvuCYPOkyLVKau V5Uq3hXlEiLFGi8tShsAr2lA2e4KiKpTe/T512PKvUpiUU22U61HZSGWkhWx0JGgTv1361hPRMau K3rvkeMWeULe2qY5JVEQl4dHvABY1vZHoex9K51rx/g15dN4Xbue2DpaYDmnOXFwIMHedOGxMALQ r8GruGtpHhzUJZm3zB7NZcZiXWUzLgxvOnHzCf4Q775bIOwQgFKdenY/fXsMhYyCU0xkOJ2m7vvO JSl0s+S+pRPYeYjR9furDeyPBshkuzbj9q2iXJWVuL92Uz1E7J/kq/1Gt9iWONquQvdiusG9twG1 yEMsLKHi4lJ8sKQsAp2rXf7q6Flf8ZfxT3nCbkhjnADQ+YaIAlhh3ZaMksW3ccNqW1PTcUjA6iR6 5HzUR5nxDCOUsrkSVZdKsd6t6Ps9PtTAdguhtStAFHvN+8pW1HY9O1aTFsEzHjLAckXcZDCENXO3 zLVcrdMS42+rTrbhbUk9Q0CnfUB6+hr4u9tvFtmLTeoMmNIcUVHz2ykqJOye/r+IqYceTDZMYyi/ PR2JLLbTEdMeQnqaeUtfcKT6Ht/+6+hcA/5L4gLr9FxCmDTEnaHNa0FxnrgRkBeWq8LoPqm4bh+c 8siMj8QtpxRysiTe2oGRSmIzt4dEcK10NyJmtpV9EuLSOkgaCiE679jelcecsYjAzHjbJLpxnCmx bzAZZuZtDSypxC2H0OB6Mv1PT09RT8XYhIOwD0rxPm7PJHG2OZwyoE3e3tPPAa0l4DpdT2+jiVj8 q+l1bix4pas4nw14dTcYPcQJgjlzx3LLZPqMJoVdxkHqP79VLqUpWiuglKUoiUpSiJSlKIlKUoiU pSiJSlKIlKUoiUpSiJSlKIlKUoiUpSiJSlKIlKUoiUpSiJSlKIlKUoiUpSiJX5J+IPkzK8y8S2RX /E71cI8xi5/Y1pchSFtOJbZV5SA2pJBHUtJV6+qzX6ZcyZHfcUwxN8x6QlqW1dLc0StAUlTbsptp aVA/IpWR20foRVHyvAThtr5VsfJeFZFKjR7deGrrJtE8ee24ptzzAlt7fWkdQT2WF+p7/KuRxKnU uiKNLlBPnIEeEFe19kb+z4Oal3ebuaWtxIkQSD0mRHnMKmc+8X/KvF/Is/BbZdbdk1nxppiyvpvM UPqlymGkokvKdT0uFS3g56qI0B29d2rx94usLmcdXXlLN+O5GPR4E+PYUP2l4SPapEhK1r8ttfQE 9DaOpWyT0ntv0rmjk/wp+ImwXS45DeMJfvKZch2W/Ls6xLSpS1FSj0J/WDuSe6BWPzTCkYTwtxXx u7Hdiy50abllzZcSUqLslzymCpJ9Clpop7/U1wats2vVc+8pAxMamiROBBIkRPIhfUb3gHs9xCzt 6NjodUcWtL6bs9lpc4kNMEnTHaG7l21inNXBeedCMV5Xs4kOAdMS5KMF7qP8kB0J6j/0d1JeQLXf 4uGmDa7a/LXcH0qkORkeaEsI0oDt395XSfwSa/KLEcWn5pldnxG1p3LvM5mCyddgpxYSCfuG9n7g a6s5h5UyHGeS3LDxtk1xtFow+IxjsFESUpCFNxkhKupI91fvhXqD2Arx9b2L4DY6ry2Y6m4gsGl0 gahDiA6T8Mj4tneC8rfezD7K9p0aFTVguhw2giMiNycY5KxFtraWW3UKQtJ0pKhog/eKtbGm14jx k5ckKUzcMgfCWlpOlpZT6EEdx6K/74qjuJvEFyVyJmVmwTJ7LYcnRcpCWnJEuCG5DLIG3HAtrpA6 UBR+H5VdT/LPC2WSRj1xmTrMi1rXEhSCncdbaToKSR1aB6R8QHbXeuTa+zX7bTrV7W4aaj2llPV2 CCYDjOQCGEgdrcjZaHE23Rc23q0iQCHO09rGY6HJHTkveFyHdzH+z77EjXuGrsWpbYKvyVr1+8g1 PJfGdiuGLLsUNp60IlPpnKQ2vr8t7p10nfxJH02PyrQY5x3BkXWDerVkMC72ltwOqcZWFEkd0j3S UnvrfcfhUf8AETe+RLPeLDLxNFwiw42/4XH7oXIcUEpbWO41oDQUNHrPrXc9nLXiXDuHXFx7RsdV aIY0GHO0n4iHiTpgiO1GCvMXdrbcSu2W9rDSQZJxnkCOvlKgfNmP3fi/hvOJFxeQh2cmDAgPsr/a qVJQtRT80kIQo/iPzqb+DDI15Lw+qZJQlEoXaUXwlQ6VuK6VqcSkfCFqUpRHp1FZHrUy5L45tHKH G8bAeQrm03cpyEFiU1pspuCGyQ42nela9/afmkn07EV94PcWu+EWzKMLvTSW5thmtRZSULC0+ctH mkhQ7EdC2z+Cvyr6LwixZwqmLa2kU8kgnMk6oPeJgd3PdeMqUalK9Dv4kEA+BXRNKUrtLdSlKURK UpREpSlESlKURKUpREpSlESlKURKUpREpSlESlKURKUpREpSlESlKURKUpREpSlESlKURKUpRFD+ XLLMv3HV6gW9gvS0NIlx20jZW4w4l5KR95LYA+81EuGOPsywzOeSr5f5SXrRld2au1nSmSpflIX5 qnEKbV+zWOpAOux16nVWvJjMTIzsOU0lxh9CmnEKHZSVDRB+4g1E+OnlWazx8GuUhxc+yeZBaU4k 7fjNdPkub7ju0tr1O9hX0Na7qLTWFU7/AIn8ldS3va1Oxq2rILXROMxLTI6QWgHuKkca5PSLrNti rVMZbhtsrRLcSkMyCvq2lsg7JR0jq2B8Sdb76pTlfNGV5ZOx694tYMgtcYNpEa6QEPgEtgq0T6d1 VILN4oOH7tlz2Ayr5KtGRM3BVr9guMNxpS5AcLYSlYCmztQ7e93BFYOd8RXG/wCUzbjbcgtpkzNP iG+oocCNBO+29jse+gK8r7Y/ulWwZ+zEl4eCdJExBxHPMYyt7gzaFrdar0aRpxM74yD65Vf4Xivh 8s18k8st8Yt43LwuBKvL0mDLWqOEJbUFaYJ6OrSlFIA9QKplPHfBnJMhU/jjxE2lM+apTpgZM2YT 5cUdkFxWgo7J+FJq5uVeOc8x/wAPnIdtt2OTrlebw3Ehxo9uR7Q44z56S6oJRtWugr323oelfm7c LDfLVOFsutmnQphUECPJjrac6ida6VAGuVYG7q8Opfu9Oah1EyNJGYG0CYE5B3X0Xgtt+5vq16N0 4FpDR2g/sgT/ACkxLjsRzXfvHHBef8VY9mGVS7Mm4XaVBRa7Mu1rEoFp4/wh9PT7w0gBIOge5+Xe qvkxJUJ5UaZHdYdQfebdQUqH4g9xXdXDeCs8Z8XYzgzKNKtVuabfP86QodbyvzcUs/nW4yrH8cvd qknILBCubbLK19EhpKj2BPuq1tJ+8elbvFPY39wYw0amktGxEiSZOceExsAvK2/tkbW4qmszWCfi GDAwMGekxO5KrDwvYMcfw9zKpjREy/KCmwf5MZBIR2/yj1K/Dpq6SkKGiAR9DVCYXzlyfkWCQsux Tw9ofx/yVpjhjKGfN8plamlBLSmQSQW1AD1Ou29itxf/ABGwY/GWLckYji670Mqu7NmYgvzUxFsv rDoIWvpWNhbRT6aIV1b16+z4bwZ3DLWnZsA7ODkb7mc4kycrwvEONU+JXL7t5PayMH4dhGMwI2Ug 5EwK9ZflmMzWpoTarc+VyW0q6FtkHq6wfnvpSnt3Hr8zqVWPFoFhul9u0T9rf5qJ0gdIAC0sNtfn 7rQqI2TNeaJt3hw71wjEtsB55KJExOVMvlhsnusNhoFeh8gRuszBeUP3X5nmODzrILXccSlttdJk +b7VHcBU0+B0J6dpAJT72uodzsValw5tvUqV25LoJyDtAH971WpxD9QylRfgNkNwRvJO43/CnlKr 25crmNyqrjG3Y+ZhiWNy93Cd7V0CKkEhDfR0HqUo9HfqGgrejoitdYue7JM4Nb5wyG0u2yEpt5So TTwkOdaJK2EISopQFFakj1AA6u/YE1t+4qQDG8fPb6LX/U0pInaZ8on0kK06VU1u5syGFklksfJH F83E4+TPCLaZqri1LSuQRtLLyUAFlatgAHfc6+RIwuS+aOTuNLbeckuXC0d/H7VI8tM9OTtJU80p 4NNOeSGSpPUVIPT36d9z23Ui2qFwaIk7ZGfmqm7pBpeSYG+DjnnEhXNSoHg2Ycm5DcEJyviqPj1t djl5uajIGppKjrpR5aW0kbBJ3vtr071Gsb8Q8LIeXJHGqcZXHgGVOt8C8mZ1ImS4iELfaS30DWgs 9+s+g7d+0ChUMwJgScgqTc0gASYkwJBH1CuGlKVhWwlKUoiUpSiJSlKIlKUoiUpSiJSlKIlKUoiU pSiJSlKIlKUoiUpSiJSlKIlKUoiUpSiJUY5BvGRYri1xyjEMR/dJc4TaXl2xp7yX5jKDtaGlEEF0 JKihJ7KPu7G91J6USYXBTPHVg8VWVK8R3A2eQ7TKN2YRJsGQRFRpEa6RkoUUKUhS9FQQlegkj4jv sQJl42+GeUc4yDGc54/xmXc3YduXDnIgPJ86OpK+tBSCUqWD1rG0gn3fQbFZXiO8G8PILhkGccd2 1t6Lk6Q9luNtrLS5b7W1NXO3LAIZuDaiohJHlvBS0q11qK/H+5+p5MxzHLxhF7yq25xiMaY8u23u POcE21yEqCXbfOhyUokR3O3WEKSeglQ2pKkqrE6gx4II3WzTuqtJzXtdkbK0/B+/k/6FYVqzKJeI 15tU6XEkt3ZDqZCf1hWnYd97p6VpA+XbQ9Kt652az3ptDN5tMOe22oOIRJYS6lKgdggKB0QQDus6 lXawNaGrE+q59Q1dicpWFev7zT/6q7/uGs2vGVHRLjPRXCoIeQptRT6gEaOquMFYiJELkviC6+IK zeGuHc8Bg4a7aYcO4PRlPuSTcelMl4uENgBorCuspHVogJ3s9qZra7Va/Dnw8xx65tt7LbXJiLuK d7lOJkrUXgg+gdJBCT6DQPoauzGXuGuHcUZ4kk8i2Zhm2IdbcjXm8Rm5XS+tTxDido1sO9vdHuke vqYaMN8P9+wTGuIbfzay4zZbs3OtDkPIoBnqklTnltpISQr3nz0gI6thIB7V1RXDnl+mBqnbcZ3/ ALzK4hty2mKeoE6Y3GDjA9PkFYGLt8+JvsY5rMwBdm9/2lNrjTUyj7iujoLiyge/072Ph3rvUQzF IwHxJ4pmIX5Vuza3vY9PV1AIElvTjClb+avdQD9En8/WLi+F4zl8K23LxN5U5dokyOr7GuOVQ+p9 ZUlSGXGPLC1BwFI6RoqCu3qKl3MuF4Pm2HeyZ/f12O2W+YxOTc0y2oqoryVdKFB10FKdlfT3Hfq0 O+q1g4NqCdiIwI3+q2y1z6Rj4mkHJnbv5dFA+D2jlLHI3M0lPUcsnyI9tcUDv7NipU0zr6bIOwP5 g/KOcW27BL54ObDjvIt3Ra7VdnJUVMpSuktyPtB9TRSSCArqRvv2OiD61dGNNcfYpxfBh2jJICcU gQBFbui5zRZU38BcU+P1ZUVE7I0OonsPSoHao/hntvFbfDsvk7Gbpj7SXUj23IYhfJW8p7q621JA Ula9ggD0Hr33f3uomAfiERyABHqMLH7nQGyR8Lpk4JcQfQ5WnmXXlTha+4nbOQr5as6xO63ePaIk 56EGbjBkr2GVkdwvQBJVtSj0nuCRuTeLv/4eMs//AAf7cxWJivH/AA1GVGzx7lmXlltxV0GI/dsl ZmQLU7pISQU6QlYBTorJI93XfVbbkbKOCOTsNuGD3/l7G48C5eT5rkO/w0vDy3UOp6SoqA95A3tJ 7b/Gmoe9Y8DY5gRz6JpPuKjC4doGATPKN+krfZzmjHHvEdwzF1aUqttpStjq1pT6kBLSe/1cUgfn XLVxtvJ+CcT4Xf5HE82ErCbsjIpN8Xd4rypKH3NupUylXmAL62kn1ICPeHqR0bmlt4l5WwFuHcOQ YLmMWWZHemSoN1ilhSmgOlqQ6QpASSpJI90k9PcfPPyDkHhPMLFcMUuXJ2JPRbvGchOobvkUrKXE lJ6ffPvDewdHRApQqe5EBs5zvt/SVNzS9+6S+OzjI33594GynFtuES7W6LdYDodizGUSGXB6LbWk KSR+IINZNR7AMftOK4ZaMcsN4kXS22+MliJLfeQ6txob6ffbSlJAGkjQHYCvOz8l8c5BcGrRYM/x u5zn+otRYd1Yeec6UlSulCFFR0ASdD0BrSLMnTkBdBrwANZglSWlYN4vVnx63u3e/wB2hWyAx0h2 VMkIZab6lBI6lqIA2SANn1IFYuP5fieWoecxXKLTeURilLyrfNakBoq3oKLajrejrf0qukxMYVtT QdM5W4pWov8AluKYm0y/lOT2mzNyFFLK7hNbjhxQ7kJLihsj6Cs6DPgXSExcrZNYlw5LYdYfYcDj bqCNhSVJJCgR6EGkGJ5KdQJ0zlZNKxLndrXZYi7jeblFgRW/jflPJabT+KlEAVgWHNcNypa28Xy2 zXhTY2tMCe1IKR9T0KOqBpImMKC9oOknK3VK1l+ybHMVhouGUZBbbPFcdDKH58tuO2pwgkIClkAq 0lR166B+laH9MvEH9KuH/wDjkX/31IY52QFDqrGmHEBTGlaF3O8HYsLOUv5nYm7LJWWmbku4siK4 sFQKUulXQo7SoaB9Un6GsmwZRjOVxnJuLZFa7xHac8px6BLbkIQvQPSVIJAOiDr7xQtcBJCB7SYB ytrStDf89wbFZLcLKMzsVmkOt+a21PuLMda0bI6glagSNgjf3GttCmw7lEYuNulsyokptLzD7LgW 262oApWlQ2FJIIII7EGoLSBJCkPaTAOVkUrykSGIjDkqS82yyyguOOOKCUoSBsqJPYADvs1qcfzX DctU+3iuW2W8qihJfTb57UktBW+kq8tR6d6Ot/Q0AJEoXNBgnK3dKis/lTi+1TX7ZdOSMWhzIyy0 9HkXiO240sdilSVLBSR9CK8P0y8Qf0q4f/45F/8AfVhSef4n0VTWpjBcPVTGlaFWd4OibbravM7E mZd2WpFvjm4shyY05sNraT1bcSrR6SkEHXbdbK63a1WO3vXa93OLb4MYBT0mU8lppsEgAqWogDuQ O59TVdJ6Kwe0yQdlmUrCtF5s+Q29q72G7Q7lAkdXlSob6XmXOlRSrpWglJ0oEHR7EEVrrhnmDWm8 N47dczsUK6uqQluDIuLLchalkBADalBRKiRoa777UDXEwAhe0CScLfUpWnx/L8Ty1DzmK5RabyiM UpeVb5rUgNFW9BRbUdb0db+lIJEqS4AwVuKUpUKUpSlESlKURKUpREqu884PxDNrlIyWK7Ox3JZM b2R682d72d+UwB2ZkpHuSWx20lwEp/kFB71YlKIqmxC3c18aWxvH7m1G5EtzDnTGuCZ/stzbZ/mu of2h3XyV5wVrsd+tTm0Xl3IJjS3rNf7O5E6lKaltJQ27tOtEoUpKtb2NH1FSClESlKURcT5fZsIv /jbvVs5DTBVZHGWS+JsnyGuoWxoo2vqTo9QGu/rV5Y1xV4XGMgt0vFoWMOXeLJbkwhGvBddDzZC0 qSgOnqIKd60fSqKzbH8FyfxsXuz8j+ymxOssqf8AaZiorfUm2MlG3EqSR7wHz71d2H8YeFbFMmt9 /wAQex9i8xXf4GtGSOPKDigUaCFPqCiQojRB9a7Fw6KbBqcOwNttvFcC1Zqq1CWsPbOTvvyx91zR 4hMWuuXeJrNLfY1OfaMWExcIyW/iWpi3sOqAO9hXQlXTrv1AD51cfIvJbHK3gvu+UeYn25KIES5I B+CU3Njhfb5BXZY+5YrVwP8ACBXL+qp/8pbquec7fK4UvOf8aR2loxfPY8a6WxISehh5uU26Uj6A dDrevXRaJ9K2ABVNGnzaGuH3/K1XE0BXq/xcXtPj/E+uPNWl/iDf9V/+vrWeH7jzw3X3iKw3TPmc bVfn/avazMu3kvdpTqUdSPNTr3AjXYdtH51s/wDEG/6r/wDX18+HTw6cNZ3w1j2V5Xh3t10ne1+f I+0ZTXX0Snm0+626lI0lCR2A9PrWFzwyk8ucR2ztv9Qs7abqlakGtDv8Y+LbfwKlPLeI8c4n4ac0 b4yiQGbXNQ28tcKSX2nHQ+0knqKldwEgdj8qgvh+488N194isN0z5nG1X5/2r2szLt5L3aU6lHUj zU69wI12HbR+dWXzjhWM8feGTKcYxG2ewWyMwhbbHnOO9JXJbUr3nFKUdkn1NVXwLxX4Zsk4nsd6 5BTZDf5PtXtftGQOxnPdkupRttLyQn9WlH8kbGj891Wk8fpnO1O+Lcb7c8/dZK1Mi7a3S34Njtvy x9lYXLWKcbYr4as2a4wjW5u2SktOuqgyjIbW6HmUk9XUruAANbqJ8E8EcL5h4f7RlWbY9HRLktTV S7oqY4wptLcp5KV9XWEJ6UoT6jXbvvvUs5Xs3G+N+GPMLBxfIt6rVFbQtTcO4GWG3FyGydrUtagT 66JqquKvCthHI/A0TODMu7GRzos5bRbeSWPNafeQ2PLKdkENpBHVvudaqabgLckvLe3vz255VarC boBtNruxty35Y/CmHgMkXpWO5dDckPPWKNPYFuUvYR5pS553SD6bT5JI+p++uYeJpsrDMjx7lBL3 RDtOQRokxR7ANuJUVDf3tpeH5V2P4K8xeybiI2qUxGadx+cuCnyWkNhbRQlaFKCQB1bUoE62enZJ JNc38R4f+7Lw8cqR2WuuTanoF2j6GyFMJdUvQ+pa8wdvr+VbNN+mrW1jBLQfPH/q1KtPVRtxTMkB xHiIMfZdBeMme/ebNhvFtscPteXX1pGk9z5SCE+n063mz/omov8A3P3+8uZ/1mF/uO1ruHMid505 wwq8yApyNgmJtGUTvpVOCSgq39StxKgP/l/PR3/fA7eoON4TyJkVzX0RLYI8x9X0bbaeUr/UKwPY aVo6hzET4k/gBbFOoK18y55HUB4Bo+5K+ueYMjnjxERuJ7dIPsmN2eUtakq2Ey1sFzf0+P2ZB/A/ hU88Euarv/Fj+KTHFe2YvMVH6VfEI7pLje/n8Xmp7/JA/AU3wNhnOvId3yXmbAcvteOy7tOfiyH5 sYPqe61IeWhAW0sBAJbGxr4dfKtvwhHyTg/xPS8CzOfFkOZTGIckx09LDzzg85txI6U698ON60AC ojWtGrVqbTRdbggloBjnI3+qpb1XC4bdOaQHkieUGNPpHRZ9gtJ8VnPeRv5dKlOYbh6yzFtzbykI c99Tbe9H3SvoWtSh73YJB1rUi5k8LbtkVZ8z8OdlftuR2+YnzI8e4BtKm+knzQp9egQQlJSFAKSo 7B+cY4DyS08Cc2Z3x7yBMbtDN3fQqHNlK6GVhtxxTJKzoJStt4kKPbY0SD2rXeJjJJ2P3iVfsB8Q +Q3GVcJHtC7PZ7m6Ylti9k9SltPFKNrKAE6G+vfbtuYq/qGspGGwIwYOOcJNH9K6pWbL5M5AcDOI ny2U88bD9zlcD4xJvcIQ7i7eoS5cYLSoMvGFJK0bSSDpRI2CR29TWdhnF3hQmYfYpd5YxMz37bFc lF299K/OLSSvqT5w0eonY0KifibmTLl4TeNbhcZb0qVKcs7z77zhW464q2vFS1KPdSiSSSe5JqQY dwz4Rp2I2Odek4/9oSLbGdl9eTvNq85TSSvaRIASeonY0NVhB0WzQSRk/D/sLM4e8u3ENaey34v9 FfHiwsWK434b7XZsIjxmbG1eGFw0xnS610uB9ZKVknqBUpR3s+tR3wTT5GK5dkHHlweI+1LPbsgi pV231strV0/UlElv8kfcakfizj4tB8ONptuFPxXbLBusSLDMaT7Q2lCG3UhIc6lFWta7kmoZep7X EeR8H8yLbULdPxGFbLkEg6V0Q0p2rQ/mvJI/+l91Xpf5LU0ty4u33kQfsqVyKV4K2waGzG0GQfLK gHikmyM35TzLIWVqNvxV2HY0n1057+07+XvokH8vxruDhr+KDBv827Z/ZW64svNilo8KM3PLqndw zHMUz3HNa6m0h5A9e/7Tzj/pV2nw1/FBg3+bds/srdUvyBQawbNMegH3WXhYJuX1HbuGr1Jj5KC+ LrOv3F8M3KLHe6JmQrFpZAPfocBLp7fLy0rH+kPwqiuHbXL4B5+xOxXF5aImbY9ES+FHsl99AIT3 9SJDfT9dL+/R3HicTe+Zuese4YxWQwldpjqcdW/sstvuI81anAAdhLSG/UHuoj51HvEZxvz3YbXa +TuQs7tV/cssttiO5CipZdjFautKz0tIBT1pSO+yCofU1ltqbW0W0XEDWDI552WC8qufXdXY0kUy ADyxl0+q6F5V4E4inY/lmZS8KiuXlcCbPVLLz3UZAaWoL0F9O+ob9NVTnhA4Z4y5E41uV7zTE490 nMXx6K26466kpaTHjqCdIUBra1H866FuGVRc44HuGXQ+kN3bF5MrpH8haoyutH+irafyqsPAZ/FB eP8AOSR/ZYtarKtVtq+XGQQN1uVKNB95TIaILSdhnZQ/mK1wLH4tOJrJaYyY8G3220xYzKSSG2m5 chKEgnZ7JAHfvV2eKT+IPL/6qz/aG6prxQPpxDxH8b8h3htxuysNxGnXwgkJLMtxbnf5kJeSdetT bxQctcdSuErzarVmFoucy9NstQ48KY28tf61CyohJJCQlJOz9w9TWQtdUdbuAnb6rGHspNuWuMb/ APzhb/wlutR/Dni8h9xLbbSbgtalHQSkTZBJJ+Q1XI+W2668sweRvEAy882m1XuEIhSTsR1KU2B9 QUJ9m/1+lXZJyGfxP4H7XDlBca6XuM7BipUClQTMfedJ+oPkKWQfrqtBx34e/EFL4jRYbLntgtWO ZVHE+Ra5MMKcV5yEfGssqWlRSlv0V20PTVZqJFF9SuSBLoE9Jk+q17gOr06VuGk6WSY6kQOmy6m4 uzFvkDjywZi2oFVzgtuPAa0l8e66nt9HErH5Vzp/c/f7y5n/AFmF/uO1s/A3lUlNhyTjC77bm49O MhtpXxJQ4ShxA/6LiCT97n/ZEfA9m2GYlactbyrLrLZlyZERTKbhPajFwJS5spC1Dq1sb19RWB1E 0qdem0c2x4TK2G3ArVLaq48nT4wAfmu0KVHrHyFgOUTjbMazjH7tLDZdMeDc2JDgQCAVdKFE6Gx3 186kNcotLTBC7bXNeJaZSlKVCslKUoiUpSiJSlKIlKUoiUpSiKtcv8OnDWd5FLyvK8O9uus7y/aH /tGU119CEtp91t1KRpKEjsPl9awLZ4VuBbPcYt2t2CeVLhPtyWHPtSarocQoKSrReIOiB2IIq2aV mFxWA0h5jxK1zaUC7UWCfAKIN8UYA1yA7ym3YNZQ8kIXO9qf7jyg1ry+vy/2aQn4flv1705A4o4/ 5SZhsZ5jqLom3rWuMS+6ypsqACtKaUk6Oh2J12H0qX0qgqvBDg4yNsrIaNMtLS0QcnG571FP0XYL +4H9GH2H/wAmfK8n2H2p74PM8zXmdfmfH3+Lf5dq2OI4jj2B49ExTFLd7Da4PmeQx5y3ejrcU4r3 nFKUdqWo9z8/pW6pUF73CCcb+fVSKTGkOAEgR5dPBanKcWsWa2CZi+TQfbLZPSESGPNW31gKCgOp BCh3SD2IqtP3onh4/o9/2tO/41XDSrMrVKYhjiPAqlS3o1TNRgJ7wCq/tHA3FFjxO7YPasV8iyXx SFz4vt0lXnKSQUnrU4Vp10j4SPSpNiOI49gePRMUxS3ew2uD5nkMect3o63FOK95xSlHalqPc/P6 VuqVDqr3iHOJ57qzKNOmQWNAjG3LoojgvFeB8au3F3CbGq2G6rS5LSmW+6hxSSrRCHFqSn4j8IH0 +Qrywnh7jnjq33O14djaYES8AJmtqlPvh4BKkgHzVqI7KUO2vWpnShq1DMuOd87xsoFCm2IaMbY2 nePFQvj7h3jjixyc9geNpti7kG0yVe1PvlYR1FIBdWrpHvq9Nb7b3oawbLwFxNj2N3nELNiqotpy ANi4x03CUS+EElI6y4VJHc/CRvejurCpUmtUJJLjnv6beigW9IAANECYwOe/rzWjw7C8Z4/sDGL4 ha02+2RlLW2yHVuEKWoqUSpalKUSSfUntoDsAK1WU8ScfZnk1rzLI8fMm9WUt+wzES32Vs+W4XEd m1pCtLJI2D6mpjSoFR4dqBM9VY0qZaGFogcowopnPFfHvJTTbWb4pCuhZSUtOrCkPNpPcpS6gpWB vvoHW6j0Lw38JW6w3DG4eBRW4N0QhuX/AAh8vOIQ4lxKfOK/NCetCDoKAPSN7FWZSpbWqNGlriB4 qrrei92pzAT4BQ3I+IuPMtxC14HkOPe12Ky+R7DE9rfb8ryWi0376FhatIUR7yjvezs96iH70Tw8 f0e/7Wnf8arhpUtuKrBDXEeZUPtaFQy9gPiAoC/wXxXIwaPxq9i3VjkWSZjML26SOl4lR6vMDnmH utXYq139PSsrJOHuOMvxS04RkWNpmWWxpZTb4/tT6CwGmi0gBxCwsgIOu6jvsTsgGppSo99UmdR6 781P6elEaRtGw26eChl34f45v2EweOrpjaXsdtpbVFhCU+jyygEJPWlYWfiV6qO97O6ktmtFux6z wbDaI/s8C2xmokVrrUvy2W0hCE9SiVHSQBskn61nVxhA/wAH5cv6yn/zVus1Km64EF38gP8AtOfk sFeqy1MtaJ0k9MNjHz8l0/ZuJeP7Dms/kW14/wCVkNzDiZM1ct90rCyCrSFrKE/CB7qRodhoEitz lWLWDNrBMxfKLcmda56UpkR1LUgLCVBQ95JCgQpIOwQe1c943c52M8Rcm8JX6QtyVjWM3CdaHXD7 0m0vxXFNn7y2pRQr5DaQPSre4E/iWwr/AOyRf/5iprU3s7ZdMEAeESCot6tOp/jDAAQSR3zBB/PN bmxce4hjOHKwCy2pTFhWy+wYipTzmm3iouJC1rKwCVq9FdtnWq+cC45w3jGzvWDB7P8AZsCRJVMc a9ode28pKUlXU6pSh7qEjW9dvxqhOIuHuNuR8n5TueaYszc5UbObnHZdW862pDfmFWh0KHzJO/Wp Hgarnx/ybmXCqb1NuVgGPnILOia6p52C2VBtxgOKOyjqVsA+gA+ZUTZ9I9pgeSdz3/Myc81SnWHY eaYAyARy7thAMclc+TYnjeZ2pdjyuyRLpBcIUWZLYWkKHoofNKh9Ro1BbL4ZOCrBckXW3cdwvaEL C0mS+/JQlQOwQh1akDv91c4cLfvRf0Z2f9KH2Z+6b+Ee3ed7X1/84c8vfl+7+z8v0+WvnupxzxF4 qg8jcQQcwajtYLHtU9ooc83y0x0x0iOPd/WaCg1r5/X51mFvUpvNFrnAZ5RMDlnMrAbmlWpiu9jC cc5Ikjfs4hX1n/FWB8oxocPOrGq5MW9anI7YlvsJQpQAJ00tOzoD13rvrWzUqZZajsojsNpbbaSE ISkaCUgaAA+Q1XM3FsXApHONuf8ADxJeTi0O2yDlLbTz4iKcWkiMEoeOy51gElI1pJ7/ABVEeAZU jFOdLpe3XVC3Zbkt+x13Y9xEhgtSGSfoVda0j8T+NYzauLSNR7IkAj5RONp71kbeNa8O0DtGCQek QZjIzHdldN2LiTj7GszuPINix/2S/XbzfbZSJb5D3mKC17bKy33UkK7J9Ruod+9E8PH9Hv8Atad/ xqprl2VIyvxH47kiXFG343mVhxiLo+6t7zDIkHX1SpSE7/CsnKP0GfvlOSf03ex+R5Vp+zvafP8A j9jb8zXlfd0+v5VlZRrAAio6S2cTO4Eb9/ksL69B0tNNsB0ZgDIJJ2O8eavzBuBeJ+Nr0rIsKxT7 OuCmFRi97dJe/VqIJHS44pPqkd9b7VYNV/wxE4iZxmRK4aaips0iYrzlRy90qfSlIP7XvsJ6fuqw K0KxcXnWST37/ddS3axtMaAAD02+gSlKViWZKUpREpSlESlKURKUpREpSlESlKURKUpREpSlESlK URKUpREpSlESlKURKUpREpSlESlKURKUpRErmOJw5yO14PZvFi8c1lDz4WiD7Yx3H2gh3fmdfl/s 0lXxfd69q6cpWalWdS+HqD6f7WvWt21/i6EeRifoqK5/4ly7K8Ytt+wCKleU2+2vWZ+MXUNiZBlM ll5oqWpKNo6itOzrYVrZ1VjcR2K64vxhi+O32J7NcLda48aSz5iV+W4lACk9SSUnR+YJFS+lHV3P pimdgjLZlOqaw3IjuXPWDROZ+Msiz1MHhl6+w8iyqdd4kpN/hRkllxw9G0qUVDYAPcbG9a3UqwHj nME3vKeTc/VDTkuSQxAjW6G51s2+Ige4z5h11rKtFR9NjY9e1t0qz7lzpwATuc/n6KjLRrIlxIGw MYnwA681ztw4/wA58WccWjA5HAkq4uWz2jclGS29sOeY+478JWda8zXr8qlF7xXN8m5h4s5AexZU CJZ4Vy+2G1TWXDBdfjFCGyQrbnvHW0Aj59hVw0qXXJc4vDQCZnfnvzRloGsFMuJAiNv4kEcu5Vbd MIv0TxCWTkKy2gKtUyxSbVeZDTzaOhaVBxlS0FQU5sgJ2kKI0N6AquYvDPIcfjnKgzYktZNF5Ddy 7HmVSmdSEpUz0HrCylHUgOjSiD2GwK6YpRt09kRGI+X99EfZU3kkk5n5gfifFc2p4az9GJ8al6yJ dvkfO2sryfpksjySt9S3V7K9LKU9CdIKientutwq2cs4Rzlnma4/xU9ktqyVq2txnm7zDia8iMhC yUuL6vi6h3A+HfcEVfVKk3bzOoAzPXmZ69yqLFjY0uIIg8uQI5joVGcIv+X3+JJey/AXcWeacCWW XLkxMLydbKtskhOj20e9SalK1nEEyBC22gtEEz/e6EpSlQrJSlKIlKUoiUpSiJSlKIlKUoiUpSiJ SlKIlKUoiUpSiJSlKIlKUoiUpSiJSlKIlKUoiUpSiJSlKIlKUoiUpSiJSlKIlKUoiUpSiJSlKIlK UoiUpSiL/9m= ------=_NextPart_01D7B08D.18DB6DF0 Content-Location: file:///C:/ACF69CEE/1112HTMLEN_arquivos/image006.png Content-Transfer-Encoding: base64 Content-Type: image/png iVBORw0KGgoAAAANSUhEUgAAAKcAAAA7CAMAAAFea1pwAAAAAXNSR0IArs4c6QAAAARnQU1BAACx jwv8YQUAAAJhUExURQAAADAyMOzs7JuinMbGxoaMh0ZJRgYGBlNTU+3t7YeNhwAAAAcHB1RUVO7u 7p2knnt7e8jIyEhLSAgICAkJCfDw8J+mn5+moDAwMIqQigoKCvHx8aCnoTExMX5+fsvLy4uRjEtO SwAAADo+OwsLC6WlpfLy8jIyMjs/PAwMDFlZWTc5NzMzMw0NDaenpzg6OFJXUw4ODjk7OaSrpQ8P D/b29jo8OoODgz9DQBAQEPf396atp5Wdljc3N9HR0REREaurq/j4+IWFhQECAVNWUxMTE62trfr6 +tTU1IOKhBQUFGFhYQMEAwMEBPv7+xkbGURIRfz8/FpfWzw8PNbW1v39/TAzMIaNh2RkZLGxsf7+ /tjY2IeOiBgYGAcIB7Kysv///52lnj8/PxkZGV5jXi8wLxoaGmdnZ7S0tNvb24qRixsbG6Coodzc 3BwcHIeMh2lpaQsMC7a2tqGpopCQkN3d3WpqagwNDDc6OJGRkSIkInh+eTg7OaOrpJKSko6VjwAA AA4PDg4PD3l/eqSspY+WkCAgIA8QD3qAe6WtpkdHR2VqZuHh4VBUUCEhIRAREHuBfKaup0hISJWV lSIiIm9vbxESEaevqOPj4xITEqiwqeTk5JOalCQkJH6Efr6+vj5BPqmxqktLSykrKeXl5SUlJXJy cr+/vxQVFaqyqz9CQExMTObm5pWclgAAAJadlycnJxYXFnR0dIGHggEBAWxxbU5OTpubm+jo6Cgo KHV1dYKIgkJFQgICAunp6SkpKQMDA+rq6pmgmioqKhkaGURHROvr61peWysrK8XFxQUFBZX3m20A AACBdFJOUwD/////////////nf////////////////////////////+a//////////////////// //////////////////////////////////////////////////////////////////////////// ////////////////////////////nuPGtPAAAAAJcEhZcwAAIdUAACHVAQSctJ0AAAYtSURBVFhH 1ZmHfxRFFMfPLjFiiR2xIIqoqFHsBRHFXlCxYBt7x46KYscuGisqlthP47NFBTUYxf5X+cpv9nZn Zy+zl5APfuHm3rz5zW/ezu5ecptGgyI0qNkkfinkEHHWMdZxPs0GLusUsvJfO+Rm67s4vJw5ZLBW VsPabKZEC6vKSrmoklfb3YIGh+ymMZeCZRtSJGoIsr7jJxUcWjRouEnNF23pNSi3sl5MGhmVynq8 4iOWUt7g/p+uBz2FpSYUcitwUjcQXUGlr4gsKr0GXUEKEJWQ7aayc7ErUj1hJpxhh1qB7YvO0qhF tnWe+BbGaPAZT0QuDr+0JjK4/GMLKZXqUbkbigO6ffmUXnJTRcnkBjaSHXFuNbqCSqEsnYHLC3eD SfmfNkgygzKTX+gKXqr5LTdAlrFUqVbZ61vEF0lF5hYTFbUy4faJ1GtpheUqkBPL7TLn3qV9w6sg QK+s5gvaasIzgPcWrSvrMo0yWBpcWulXFku15jGlYHqWrYNeFUtN1UbWMmXZQj0PG3J0PpJl7Mr+ hF9T6Q/kQrwp0cci9hDdrOkSNFOGz7ProKpamNr6OYi6dTzAdHLwfHdwgHSAmapWpOTO1Laqirqm v6ieJ+ib+5G2MEURL4I5sgGFSvll7UTnhqommNRa5EJyps6tr+0CbasvGTn4U6VBv0x2onrVyrOg zZSRYVNbk1sYOrc/0aNWUYfgjjZbD/eWICwzwMvq3qMfIfuYkLozkIvCpvPZ8mJ0YwSfPWfMQVCN VtquzlofaOk0HkYwdmzW2Bu7OHbs0bgA0djRlfN83Uq/BN0qTEXvoVum5fkQtMx0pGLwwofJzcEy ZEpknuI1X8R6mVguht5zk0yHVIj3ZB/RGW1MTeZbJAPgWbBsYzpkMppsb8gGZJ4qyiB6TYdDfIF4 n4N0EfMkOkQ0OSoKRZneMy7ynqrNMWrPc+gIKHfVVibE9emeMOHXP4voGfdgT6WethWv1WaZ5ulb DaAoYMOZ5ylIF6npaQcPzwpJeOwLp9Fpbp51oSiiUvM8l45CMkA9D6Rp6kJ0t7ZtPNl0Lo+q4Guk QtQT2+RO0vZXaYi2N0EJWXOWNFWComeOqjIFMaSl6EQwz5IpVdx2SWSeBVPu6mhndMkPzicDU7V8 k9sO0R/GbC5vmaNPdIj9gGePfg2UwbaWsiwvrGvHwS8N7OJ9HmuFURx1TyS3w8iedLW6epCMottj W1SB9yS6FX4jbaUdd5qnMHw6gjZwnd11PMeGteI5he79dl3nAJrSIL3h13G6+BxV1nnnlyu+uALx 6Ogbxtkj+g2pesTr/A6eLTbBSCfAIkfFc4I2ROr8F2bM94tuW4WQeRqCesjMPeVj2TNbMosxmkqp TjEhehWeHv46KNwDUToyCx5y6hG+zSEEiQR1ii19BLcAHTsbwkR4BmbbfITaORyaJAp1Pi9Wm8Mp ggzX2geWY2oJHjoaqhTydW4jZcAmzlaigDoBvtJXY6YdI6MPqASOIUshV+cHYgOTKuaJxuQJ5P1k ojD6OsUFHsdJTOSfYQlPaOyul9j0I8NSm8XIPGHUdYqJOXwl4YxLLSEtLdNWByVQfQJ+jtBrf0Dp vQP90dc5l4N9JNiLX1nWcyUnVJ/AO0RDmKbff/Jek2r4MJE6p+ftsqznLk7sqBMSYG32IRfUyTFE SUTqvI+DCzVisuwEbZ17iROqT+J2Pz2o88RaLkzs+uyRcPBaS0hLf2urgxKoPpFs4oT9BA3ljK2H 8URadeYKdZMlLt7vqzR2J0ts+kTsgd0PNt25D7X7MwaTydW5mOcPw60SWcTkNbhRZrU4FOk65Ops 6tcY1BPnOVH0Q16X/r6+TqcW62x+JmXsgpoiyHD93RwTpM4Htha0q5W8j7ICdEwvf9WPLwdxneBx KQEPBrLPJYDfP2eKxA5m3Ml9h9UqmkPoEc36/Phvbmr9er9Eh59Cb7zJf9eWZyvCs+i36MHIdujX YsCtXL7SuYvoLXek3KnHIF+L4JkA6lF++mvjE+5HrPwOUU0G3Bqi5W4nok3l74jI1qT87OJgVBXQ jeH6aJ1XWYGdlhmpUxjeDdUpnyLbIVrndWulznWP/0edRP8BH8adHGjCDpYAAAAASUVORK5CYIJ= ------=_NextPart_01D7B08D.18DB6DF0 Content-Location: file:///C:/ACF69CEE/1112HTMLEN_arquivos/filelist.xml Content-Transfer-Encoding: quoted-printable Content-Type: text/xml; charset="utf-8" ------=_NextPart_01D7B08D.18DB6DF0--